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ABSTRACT
Over-modulation of the sympathetic nervous system and reduced heart rate
variability (HRV) are commonly overlooked components of pain, poor cognition
(decreased attention, recall, and cognitive processing), depression, stress, and
fatigue. HRV Biofeedback (HRVB) training induces HRV coherence to balance the
autonomic system. Paced breathing (~6 breaths/minute) increases HRV
coherence.

This randomized, controlled intervention trial tested the hypothesis

that HRVB would improve HRV coherence, pain (severity, interference, and
catastrophizing), cognitive performance, and reduce depressive, stress, and
fatigue symptoms and pain medication use in veterans. Participants were
randomized to previously established HRVB or control protocols. Each participant
completed a Baseline Assessment, 6 weekly training sessions, a Post-training
Assessment, a Booster training session and Assessment (1-month post-training),
and a Follow-up Assessment (2-months post-training). Outcomes included: 15minute resting HRV recordings (HRV Coherence Ratio), Brief Pain Inventory
(severity, intensity), Pain Catastrophizing Scale, pain medication use, Paced
Auditory Serial Addition Test (PASAT), Hopkins Verbal Learning Test-Revised
(HVLT-R), Psychomotor Vigilance Task (PVT), Beck Depression Index-II (BDI-II),
Perceived Stress Scale, and Multidimensional Fatigue Inventory. To date, 85
patients

completed

Baseline

Assessment,

Assessment, and 50 completed the
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63

completed

Post-training

entire protocol. Patients in the HRVB group had elevated HRV Coherence Ratios
at the Follow-up Assessment relative to baseline (0.17±.02 vs. 0.45±0.08,
p<0.001), whereas no differences were observed among controls (0.17±0.02 vs.
0.19±0.03, p=0.55). Compared to baseline scores, the Follow-up Assessment
resulted in a reduction in Pain Interference scores (5.67 ± 0.19 vs 4.69 ± 0.37
p=<0.01) and an improvement in Mean Reaction Time (431.59 ± 17.32 vs 407.50
± 17.71, p=0.04). No statistically significant differences were noted among
controls. The intervention was received, a statistically significant increase in the
HRV Coherence Ratio was observed in the intervention group over time, whereas
no changes were seen in the control group. Those in the intervention group
improved their reported pain and depression symptoms, reduced non-steroidal
anti-inflammatory medication use and reaction time as compared to the control
group. Non-pharmacological therapies that improve pain, cognition, and
depression would benefit veterans. HRVB is a valid, quantifiable, easilyimplemented intervention. Results from mixed effects statistical models testing
study hypotheses indicate the potential benefit of HRVB in this trial.
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CHAPTER 1
INTRODUCTION AND SPECIFIC AIMS
1.1

INTRODUCTION
Heart rate variability (HRV) has repeatedly been used to characterize

current health status and to predict future outcomes.1 Wide variation in heart rate
throughout each day is reflective of a higher level of resilience and ability of the
human body to respond to both internal and external stresses. Conversely, minimal
variation of heart rate has been tied to inflexibility of the autonomic nervous system
(ANS) to respond to stresses.2 Reduced HRV has been associated with cardiac
death3, chronic pain,4, 5 mental health disorders,3, 6 along with reduced cognitive
function.6

7, 8

Over time, this may lead to chronic health issues which may cost

billions of dollars annually in direct and indirect costs.9, 10 It is estimated that by
the year 2030, crude (age-unadjusted) prevalence of cardiovascular disease will
make up 40.5% of the United States adult population (age 18+ years) with around
$818 billion in direct healthcare cost and around $276 billion indirectly due to loss
of productivity.10 The ANS plays a role in cardiac function. Therefore, if cardiac
autonomic function is poor, then heart failure and death may result,3 thus leading
to a shortened life expectancy, fewer productive years of employment, and a low
quality of life.

1

As a result of ANS dysfunction, decreased HRV has been associated with
chronic pain,4,

11

and with decreased cognitive performance,4,

12

as well as

prolonged recovery in those who sustain concussion.5 Chronic pain is associated
with changes in cognitive performance.13 Chronic pain has been defined as pain
lasting more than three months. Approximately one-fourth of the general
population seeks treatment for chronic pain through their primary care providers.14,
15

While

both

pharmacologic

(i.e.,

acetaminophen,

nonsteroidal

anti-

inflammatories, and opioids) and nonpharmacologic treatments are provided to
treat pain and other conditions, opioid prescriptions have been provided to millions
of people across the United States to treat pain.16 In 2012 approximately 25 million
US adults noted having pain during the 2012 National Health Interview Survey.17
According to the Veterans Administration, the Department of Defense, and
the Centers for Disease Control and Prevention, more than 200,000 people died
between 1999 and 2016 due to prescription opioid overdose.16 The prevalence of
opioid prescriptions has risen among veterans from 18.9% to 33.4% between 2004
and 2012.18 This rise in prescription prevalence increased nearly 77%.18 Deaths
in 2016 were five times that of opioid related deaths in 1999.19 As concern of the
opioid epidemic18 grows due to potential for addiction to medications and
unintended consequences, safe, non-addictive alternatives are needed that can
be used anywhere, under circumstances that may reduce injury and illness. HRVB
will be evaluated here as a potentially safe, non-addictive intervention in a
randomized controlled trial to determine if it is effective at restoring autonomic
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balance by decreasing pain and improving cognitive function and psychological
well-being among veterans.
This dissertation included three aims within a unique population and source
of data. The first chapter provides the introduction and specific aims. Chapter 2
provides the background information, rationale for the proposed specific aims and
defines the study population. Each of the three specific aims utilized a population
of United States military veterans over the age of 18 who have chronic pain and
are registered patients of the William J Bryce (WJB) Dorn Veterans Health
Administration in Columbia, South Carolina. This document is formatted with
Chapter 3 describing the methods, Chapter 4 describing the results for the
outcomes, and Chapter 5 providing discussion for the outcomes.
SPECIFIC AIM 1: HRVB AND CHRONIC PAIN
HRVB is thought to be a safe, effective, non-habit-forming intervention to
reduce pain4, 20-23. This involves coaching a participant to breathe about 6 breaths
per minute. When using paced breathing, also referred to as resonance frequency
breathing, through the technique of HRVB, studies have shown a balancing or
entrainment of the ANS referred to as HRV coherence.24 HRV coherence
enhances the parasympathetic vagal tone thus allowing the body to establish ANS
homeostasis in those with increased sympathetic activity.24 Paraphrasing Porges,
homeostasis is a dynamic regulation within a functional range for living systems
to maintain internal states.2 With the application of biofeedback, participants have
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been shown to improve HRV, improve sleep, cognitive function, and reduce pain.4,
24

This randomized controlled intervention trial examined the efficacy of HRVB to
reduce pain (severity, interference, and catastrophizing), improve cognitive
function, and reduce reported symptoms of depression, stress, and fatigue among
U.S. military veterans with chronic pain utilizing volunteer veterans at the WJB
Dorn Veteran’s Health Administration in Columbia, SC. Two arms were used
where a control group was compared with an HRVB intervention group. First, we
examined if receipt of the intervention (HRVB) was successful in the Intervention
group by assessing outcomes of HRV parameters using a linear mixed model with
group, time, group by time interactions. Next, the primary dependent variables
were pain severity (PS), Pain Interference Score (PIS), and Pain Catastrophizing
Scale (PCS). These measures were reported using a linear mixed model with a
group, time, group by time interaction. Lastly, we evaluated pain medication
usage. This was categorized based on the type of medication (i.e. Non-Steroidal
Anti-Inflammatory Drug, Opioid, etc.) evaluated using a linear mixed model with
the same group, time, group by time interaction. Socio-demographic (i.e. gender,
race, income, education, etc.) baseline differences were examined for
confounding; any differences that existed were controlled for in the regression
models.

4

The research aims and hypotheses for HRVB and Pain were:
1.1.1 Quantify the changes in HRV time and frequency domain measures among
the

Baseline,

Post-Training,

and

Follow-up

Assessments

using

biofeedback. Hypothesis: HRV will improve in the intervention group
through the receipt of HRVB over time as compared to baseline.
1.1.2 Evaluate changes in pain resulting from improvement in HRV. Hypothesis:
Improvements in HRV scores and coherence will result in a decrease in
pain severity and intensity which will be measured from Pain Severity Score
(PS) and Pain Interference Score (PIS) over time as compared to baseline.
1.1.3 Elucidate differences in pain catastrophizing and in pain medication use.
Hypothesis: There will be a decrease in the Pain Catastrophizing Score
(PCS) and a reduction in pain medication use using HRVB over time as
compared to baseline.
SPECIFIC AIM 2: HRVB AND COGNITIVE PERFORMANCE
Reduced HRV has been associated with poor health outcomes, indicative
of reduced resilience in responding to physical and psychological stress,25 and
diminished cognitive function.4 With the application of biofeedback, participants
have been shown to improve cognitive function.4
This study used the same veteran population described above from
Columbia, SC. Dependent variables were cognitive function outcomes as
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measured separately by the Paced Audio Serial Addition Test, the Hopkins Verbal
Learning Test-Revised, and the Psychomotor Vigilance Test.
The research aim and hypothesis for HRVB and Cognitive Performance was:
1.2.1 Quantify the changes in Paced Audio Serial Addition Test (PASAT),
Hopkins Verbal Learning Test-Revised (HVLT), and Psychomotor Vigilance
Test (PVT) reaction time and total number of lapsed (missed) response
measures between Baseline, Post-Training, and Follow-up Assessments
through the use of HRVB. Hypothesis: The number of correctly added pairs
of PASAT numbers will increase, the mean HVLT score for the number of
words correctly recalled will increase, the PVT reaction time will improve,
and the total number of PVT lapses will decrease in the intervention group
through the receipt of HRVB.

SPECIFIC AIM 3: HRVB, DEPRESSION, FATIGUE, AND PERCEIVED STRESS
Stress has been linked to negative changes in health such as elevated blood
pressure and heart rate, increased inflammation, changes in the immune system
and nervous system, along with depression, and anxiety.25 Stress has been
associated with developing illness from viral infections such as the common cold
or influenza.26 Increased psychological stress has been associated with lower
HRV. HRVB can help reduce depressive symptoms, anxiety, and stress.25 HRVB
has been suggested to improve symptoms of depression,27-40 stress,
fatigue.44,45
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25, 41-43

and

This study assessed subjectively-reported depression, perceived stress, and
fatigue in U.S. military veterans with chronic pain utilizing the same veteran
population as previously described for aims 1 and 2. The primary dependent
variable was self-reported depression, quantified using the Beck Depression
Inventory-II (BDI). Depression was assessed using a linear mixed model with a
group, time, group by time interaction. A second outcome was perceived stress
score (PSS). A third outcome was self-reported fatigue using the MFI. Separate
analyses were conducted to assess for General Fatigue, Mental Fatigue, Physical
Fatigue, Reduced Activity, and Reduced Motivation utilizing the same linear mixed
model described previously.
The Research aim for HRVB, Depression, Stress, and Fatigue was:
1.3.1 Elucidate differences in depression, perceived stress, and fatigue.
Hypothesis: There will be a decrease in the Becks Depression Inventory
(BDI), less perceived stress, and a decrease in the general fatigue, mental
fatigue, physical fatigue, less reduced activity, and less reduced motivation
through receipt of the intervention HRVB.
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CHAPTER 2
BACKGROUND
2.1.1 Heart Rate Variability and Biofeedback
The human heart rate is the pace at which the heart responds to stimuli
throughout the day. This is driven by signals from the ANS46-48 which is comprised
of two drivers: the sympathetic (action) and parasympathetic (rest) systems.2 The
ANS is a network of neurological signals sending and receiving messages from
the brain and other organs. Neural control for both sympathetic nervous system
(SNS) and parasympathetic nervous system (PNS) originate in the brainstem. The
sympathetic system primarily responds to stimuli external to the body with the
mobilization of metabolic resources while the parasympathetic system primarily
responds to changes within the body to maintain homeostasis, allowing for rest
and recovery.2 Heart rate fluctuates continuously by adjusting to stresses from the
surrounding environment. These rate alterations are also referred to as
oscillations.1,

48

Respiratory sinus arrhythmia (RSA) is the change in HR that

occurs with each breath; the heart rate accelerates with inspiration and slows with
exhalation.2,

20

Messages transferred via efferent vagal pathways promote

parasympathetic control and are thought to decrease inflammation, improve gas
exchange in the lungs, and promote resilience and resonance.

8

HRV measurements can be obtained to assess the balance in the SNS and
PNS through short-term or long-term (24-hour) recordings of heart rate. The
recordings produce variables in time domain49 and frequency domain50 that may
assist in determining health status. Normative values of these heart rate variables
have been established in children51, 52 and adults53 using standard bandwidths,8
as introduced by McCraty.7
As described by Jarvelin et al., in an electrocardiogram, the peak of a
normal QRS complex is the R wave. The distance from one R-wave to the next
R-wave is a time interval and will vary from beat-to-beat. Variation in the distance
between successive heart beats over time is called HRV and may provide objective
findings.54-56 The R-R interval has also been referred as N-N (normal-to-normal).54
Changes in or lack of changes in variation may be reflective of both psychological
as well as physical stimuli placed upon the human body and how well the ANS
reacts to the stimuli.57 Essentially, the greater the variation, the better one is able
to respond, thus exhibiting better overall health.56, 58 Anything that affects the ANS
such as psychophysiological stress or recovery of the ANS should be evaluated
as it relates to HRV54. Such things that influence HRV include age,59, 60 fat mass,52
gender,59, 60 cardiorespiratory fitness,61 physical fitness,52 health,59 medication,59
circadian changes,46 and smoking.59
As noted by Lehrer et al.,62 the field of psychotherapy evolved out of
necessity during World War II where physicians were the primary provider of
psychological care. Over time as the field of psychology and later behavioral
psychology developed, deep breathing and muscle relaxation techniques were
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found to be beneficial in treating individuals with anxiety, sleeping difficulty,
headaches, and high blood pressure.62 These techniques emphasized the use of
abdominal breathing for breathing retraining.62

Hyperventilation has been

attributed to the use of thoracic muscles during breathing and Lehrer et al. noted
that many authors have cited the use of thoracic breathing as being associated
with both emotional difficulties and complaints of the body.62 While relaxation
techniques may attenuate SNS activity and feelings of anxiety and frustration,
during the 1980s and 1990s, Russian scientists were exploring the use of resonant
frequency breathing to provide more flexibility within the PNS.62 Hyperventilation
involves an increase in breathing rate often accompanying stressful events,
whereas controlled breathing at a rate of around 6 breaths per minute leads to an
increase in positive emotion62, 63 as well as increased HRV. Changes in HRV has
been attributed to changes in health.5

Increased variability is associated with

improved health39 whereas decreased HRV has attributed to decline in health.
Decreased HRV has been associated with depression as well as with the use of
antidepressant medication.41 HRV has been evaluated in adults to monitor
outcomes after significant events and even predict outcomes over several
decades. Since the 1970s, examples include congestive heart failure,64 post
myocardial infarction, alcoholism, and diabetic neuropathy.46
When synchronization between the heart, lungs, and brain is reached, HRV
coherence develops.24 HRV coherence can be achieved using a paced-breathing
technique called resonance frequency breathing.24 Each person has a unique
frequency in which parasympathetic control is promoted and HRV coherence is
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achieved, which usually occurs at ~6 breaths per minute (or 0.1 Hz).

20, 36, 65

Coherence refers to oscillations (heart rate and respiration) that occur at the same
frequency. When resonance frequency breathing is achieved, oscillations in heart
rate and respiration appear, are in phase, and HRV coherence is maximized.7
McCraty et al refer to HRV coherence as “an optimal psychophysiological state”.66
This frequency maximizes efficiency of gas exchange in the lungs, may lower
blood pressure, improve depression and anxiety, decrease pain, improve athletic
performance20 and increase HRV.9 As quoted by Swanson et al. “Increased HRV
is synonymous with parasympathetic tone or vagal tone”.9 Reduced HRV has been
associated with poor health outcomes and is indicative of reduced resilience in
responding to physical and psychological stress.

Those with positive affect

(positive thought processes) performed better with HRVB in cognitive tests
suggesting that positive thoughts influence the benefit of HRVB67 which is
consistent with other investigators who have stated that negative thoughts can
drive negative results and conversely with positive thoughts and outcomes.68
Porges notes that this technique influences the parasympathetic nervous system
through activation of the nerve fibers which regulate blood pressure and heart
rate.69 HRVB is a non-pharmacological treatment in the reduction of chronic pain,4
has influenced vagal activity,65 and inhibits spinal column pain pathways.4 HRVB
has been shown to improve anxiety,37-39, 70-72 improve sleep and cognition with
decrease in stress and pain,4,

21-23, 39, 73-75

depression,32-41 insomnia,78 heart disease,9,
stress disorder (PTSD)8, 36, 83

11

79

decrease blood pressure,76,

77

asthma,80-82 and posttraumatic

2.1.2 HRV, HRVB and Chronic Pain in Veterans:
Pain has been labeled as the fifth vital sign in the past few decades, has
been used as a subjective measurement, and appears to be noted with more
frequency in the news. Pain not only interferes with activities of daily living and
quality of life,84-86 it is one of the leading reasons for primary care visits.87,

88

Treatment for pain has led to stronger, more potent, and potentially addictive
medications to be prescribed in higher quantity and in frequency to the point that
the world is facing an opioid epidemic.89, 90 Despite the increase in treatments, pain
appears to be worsening globally, not improving. Chronic pain is defined as pain
that lasts longer than three months14, 15 and has been shown to disrupt sleep,
cognitive function, increase fatigue and depression. It is thought that each year,
over 100 million people seek treatment for chronic pain in the US resulting in
medical costs near $635 billion both directly and indirectly.91 Of those taking opioid
narcotics for chronic pain, upwards of 60% may be prone to abuse.92 In 2015, it
was estimated over 2 million Americans had a prescription pain medication abuse
disorder while nearly 600,000 used heroin.93 The average annual cost for opioid
rehabilitation with methadone is approximately $4,700 per patient.94
Military recruits are medically screened out of the general population and
tend to be healthier than the general population95 whether the individual was
drafted or volunteered. Veterans comprise approximately 10% of the US
population.96

During their time in service, military personnel have access to

comprehensive health care95 with routine maintenance and care provided for
exposure to both combat related and non-combat related injuries and illness.95
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However, following military service, veterans tend to report higher chronic pain
than the general population.97-100
Among age-matched veterans and nonveterans, those who have provided
military service tend to express higher chronic health and psychological concerns
than nonveterans.99 Among some of the symptoms, veterans who deployed for the
Persian Gulf War (1990-91) have a higher prevalence of abdominal pain,101-103
and pain in the joints relative to veterans that did not deploy during that time101-107
and higher prevalence of arthritis,98, 108-112 backpain,103-105, 111 fibromyalgia,109 and
headache102, 106 in veterans relative to nonveterans. This is most striking among
those engaged in conflicts in Iraq and Afghanistan and has been shown to interfere
with activities of daily life (ADLs).113, 114
Pain in veterans has been associated with physical and mental problems.4
Opioid and opioid receptor binding medications are standard for use in chronic
pain and have been associated with physical or psychological side-effects ranging
from constipation, nausea, and intolerance to the medication, as well as
addiction.115 Opioid prescriptions are more likely to be prescribed for pain to
veterans with mental health conditions than to veterans without mental health
conditions.116
A relative increase of 76.7% in opioid prescriptions among veterans
increased between 2004 and 2012 from 18.9% of all veteran outpatients to
33.4%.117 This increased usage of opioids has the potential to alter cognitive
performance. In a study by Sinnot et al.,29 between 2000 and 2007, low back pain
prevalence rate increased 4.8% as compared to diabetes 4.4%, hypertension
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4.1%, and depression 3.8% among VA users. The rate in number of individuals
with low back pain rose from 10,955 to 15,205 per 100,000 Veterans
Administration (VA) users.29 Quality of life relating to health among active duty
men has been reported by Barret et al., to be more likely to be physically limited
from activity, report pain, and report inadequate rest as compared to men who
have no military service.113 Further, the authors note active duty men to be five
times more likely to have pain and limited activity for 14 or more days as compared
to men with no military service.113 Orthopedic injuries leading to limited physical
activity and chronic joint symptoms may be associated with increased prevalence
of arthritis among veterans as compared to nonveterans.108
Pain has been associated with changes in HRV23, 39 and with changes in
memory.30 In a study of older adults by van der Leeuw et al., women, African
Americans, and those with fewer years of education were more likely to have pain
interference or severe pain.118 Pain severity was found to produce more disability,
especially beyond the age of 65.84 It is conceivable that a reduction in pain may
also facilitate improvement in memory. HRVB has been shown in studies to be an
effective tool in reducing pain in veterans.4 Therefore, HRVB may be effective at
improving both pain and memory.
2.1.3 HRV, HRVB, and Cognitive Function in Veterans
According to the Centers for Disease Control and Prevention (CDC), it is
estimated that over 16 million people in the U.S. have some form of cognitive
impairment (more than twice the population of New York City) and over 10 million
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family members provide care for these individuals.119 Cognitive impairment may
range from mild to severe in which changes may be noted in difficulty
concentrating, trouble remembering or learning.119
Working memory is believed to correspond to activity within the prefrontal
cortex (PFC).120 In times of stress, the PFC may be bypassed or taken offline
allowing the amygdala to take over and respond to threats, then return to PFC
control when the threat subsides for deliberate and conscientious behavior.121 This
inhibitory control is associated with executive function, emotional control, along
with working memory.121 Normally, the amygdala can be associated with fear or
response to threats. When the PFC is online and working appropriately, while it
may not suppress fear, it may help to remember strategies to contend with fear.55
Thayer et al. suggest that when the PFC goes offline, more energy is mobilized by
the amygdala to be able to respond to perceived threats and a decrease in HRV
has been noted.55 Cognitive performance and the PFC have been linked with
HRV.122 An intact, activated PFC with vagally-mediated HRV demonstrated
increased executive function, increased correct answers, and faster reaction times
in several studies with HRVB.122-124
In a study by Stricker and colleagues, memory impairment was more likely
in those with PTSD.125 Among veterans of the Persian Gulf War (1990-1991),
those with PTSD performed more poorly than those without PTSD in tests
measuring attention, learning, and memory.126 In a prospective cohort of over
1,200 active duty U.S. Army Soldiers of the Iraq conflict (2003-2005), study
participants conducted pre- and post-deployment assessments. Those who
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deployed were found to display more tension and confusion, decreased sustained
attention, decreased verbal learning, decreased visual-spatial memory, yet
exhibited increased reaction time.127 In a stratified, retrospective cohort of over
181,000 male veterans without dementia, participants were followed from 19972007. The 7-year cumulative incidence rate (CIR) for dementia among those
participants with PTSD had a CIR of 10.6% as compared to those without PTSD
with a CIR of 6.6%. Those with PTSD had nearly 2-fold incident dementia utilizing
Cox proportional hazard models.128
Weiner et al. noted that a decline in memory and learning was found in
those with chronic back pain129 and chronic pain was associated with changes in
memory and emotional decision-making tasks.30,

130

Cognitive functions are

thought to change in accordance with chronic pain, in which pain may be a
distraction from required attention leading to poor cognitive outcomes.131 It is also
believed that education may be protective in preventing cognitive decline and
influences neuropsychological performance.132-136
In a quasi-experimental study design of 37 male Norwegian sailors, upon
completion of eight weeks of basic training, participants were transferred into a
training program for another eight weeks. Assignment to fitness training versus a
fitness detraining was based on their follow-on duty assignment. Those who
maintained fitness training continued three hours per week of physical fitness
whereas those in the detrained group went on-board ship for service. Those in the
fitness trained group demonstrated higher HRV, faster reaction time in executive

16

functions, and provided more correct answers in an N-back test, recalling numbers
previously seen.122
In another study by Hansen et al., 53 Norwegian male sailors provided a 5minute baseline HRV recording. HRV categories were split with the median of
RMSSD. The high HRV group demonstrated faster mean reaction time, fewer
errors, and more correct answers than the low HRV group.124
Prinsloo et al, reported using a randomized HRVB and control group study
in 18 male participants with work-related stress. Upon enrollment, participants
were stratified randomly based on age initially and then later randomly allocated
to either the HRVB or control group. Participants were taught how to use an
electronic handheld biofeedback device, to follow a wave form with inhalation and
exhalation using time-domain metrics rather than true resonance frequency
breathing. Baseline recordings were obtained including blood pressure and heart
rate. This was followed by a five-minute Stroop task (responding to squares and
color words in different colors), a five-minute rest period, and finally the ten-minute
HRVB intervention. Those in the HRVB group made fewer mistakes and improved
reaction time as compared to the control group.123
In a cross-sectional study of middle-aged male twins in the Emory Twin
Studies from the Vietnam Era Twin Registry, participants remained on the Emory
campus, provided 24-hour leisurely ambulatory HRV recordings, and conducted
BDI and cognitive testing. HRV was positively associated with verbal memory.137
Twin HRV recordings of less than 18 hours were excluded. Sutarto and colleagues
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reported among thirty-six operators randomly allocated into HRVB or control
group, participants were provided five-weekly HRVB sessions of 30-50 minutes
each. Improvement in attention and memory were noted in recipients of HRVB.138
2.1.4 HRV, HRVB, and Depression in Veterans
In the U.S. in 2012, direct cost of $300 billion was spent on mental health.139
In the Department of Veteran’s Affairs in 2010, over 110,000 primary care visits
had new incidence of depression in veterans.140 The veteran population comprises
approximately 18 million people of the U.S. population141 and major depression in
veterans is estimated to be between 12-30%.142 A recent publication by Liu et al.
reported depression prevalence among U.S. military veterans increased from 9%
(2007-2008) to over 14% (2015-2016) based on a sample from the National Health
and Nutrition Examination Survey (NHANES) and over 16% of veterans reported
having little energy over half the days in a two-week period.139
Arnsten and Goldman-Rakic described that the PFC may go off-line when
under stress for survival purposes however when sustained, this may be not be
conducive for society as the PFC helps with executive control and inhibition143 This
sustained off-line process can lead to psychological disorders to include
depression, anxiety, and PTSD.144 What’s more is that reduced HRV is connected
with depression.32, 144, 145 Reduced HRV has been reported with depression in both
healthy and unhealthy populations146-148 and it has been improved through the use
of HRVB.35, 36, 40, 41, 146, 149 In a randomized controlled trial of 38 participants (ages
18-70 years) with unexplained somatic complaints, HRVB training over the course
of 10 weekly sessions helped resolve depressive symptoms as early as 5 weeks
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after treatment.35 Depression has been associated with chronic pain,29,
concussions,27,

28

30

cardiovascular risks,150 and is observed in children with

anxiety.31 Depression has been associated with heart failure and improved HRV in
heart failure patients146 has demonstrated improved survival151 and better
outcomes.152 However, one study suggested the direction for the development of
depression was due to reduced HRV, whereas in the presence of antidepressants,
depression reduced HRV.153
2.1.5 HRV, HRVB, and Stress in Veterans
In a review by Subhani et al.,154 stress is believed to be associated with
impairment of memory,155 and changes in cognitive health156 possibly resulting in
atrophy of the PFC and hippocampus.157 As the PFC has been connected to
attentional endurance, changes in executive function may displayed.158 The link
between the PFC and the heart may reside in both direct and indirect pathways
which control the heart rate via the vagus nerve. This PFC-cardiac connection
effects the PNS and SNS as well as influence baroreceptors to modulate HRV. 158
This interaction with the baroreceptors has been associated with increased mental
workload and cognitive demand.158-160 Cognitive function can be impaired by
chronic psychological stress.123, 161-163 Chronic stress has been associated with
major depression and PTSD, especially in military veterans.142 PTSD in veterans
ranges from 6-31% as compared to 6-12% of the U.S. population.142 As women in
the military in past conflicts may have been relegated to nursing or clerical roles,
more recent conflicts have exposed women to greater combat intensity.142 Since
past medical studies have examined combat-related stress in male veterans, this
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new dynamic may be considered in future studies including more women. The
World Health Organization has referred to stress as a nonpsychotic mental health
disorder164 and even provided a diagnostic classification code for this. Chronic
psychological stress has been associated with reduced HRV.123,

165-168

Some

occupations demand intense mental focus and workload such as air traffic
controllers, pilots, and surgeons. Utilizing the National Aeronautics and Space
Administration Task Load Index (NASA-TLX), subjective mental load has been
measured and has demonstrated correlation of HRV to both reduced attention and
mental fatigue.158 When time-on-task was recorded, lower HRV was found with
longer tasks requiring sustained vigilance and attention.158 HRVB is believed to
help reduce stress.41-43 Prinsloo et al., reported participants in an HRVB group felt
more relaxed and alert.123 Slowed breathing with the abdomen has been found to
increase HRV and reduce anxiety in musicians.43 Pregnant women who completed
HRVB training reported reductions in stress compared to women who did not
receive HRVB.42
2.1.6 HRV, HRVB, and Fatigue in Veterans
Fatigue is experienced by many people, but they often find it difficult to
describe. Persson and Bondke Persson described fatigue as subjective and vague
but provided three characteristics: develops gradually, while different than
weakness is relieved by rest, lasting more than six months.169

Smets et al.

describe fatigue as one of the most commonly reported symptoms in cancer
patients and that fatigue is a symptom often relieved via convalescence.170
Schiehser et al. depict fatigue as being a multi-faceted entity with physical and
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mental components, involving alterations in motivation, initiating and sustaining
tasks, and may be associated with trauma such as traumatic brain injury,
depression, and anxiety.171 Fatigue is often a symptom described by healthy
people after being sleep restricted, after physical exertion, or in post-surgical
patients172. Fatigue is associated with outcomes of the Psychomotor Vigilance
Task, even among those who are not injured.173 While fatigue is a common
concern expressed to medical providers, it can also be a precursor to diseases or
disorders.172 Fatigue is experienced in approximately 38% of community dwellers
and the prevalence of fatigue lasting more than six months in the general
population may range from 2-11% at any given time.174 HRV is reduced with
fatigue175 and has been noted to be lower due to both mental effort and workload
associated with fatigue.166,

176, 177

Difficulty with concentration and memory

comprise mental fatigue, is common with concussion173 and in workload.178 Mental
effort and HRV power have been found to be inversely related126, and relationships
between HRV, mental workload, and mental fatigue have been reported.176, 179
Reduced HRV has been reported following physical or cognitive challenges as
well.180 HRVB has demonstrated improvement in both fatigue and in depression.44
Reduced motivation to initiate activity may be described in those who report feeling
fatigued along with depression.172 A study found improved motivation among
police officers who received HRVB. 45 A separate study found improvement in four
of five fatigue subscales after HRVB. Improvements were reported in general
fatigue, mental fatigue, physical fatigue, and reduced activity; however,
improvements were not observed in reduced motivation.44
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In summary, HRV has been shown to be reduced in those with poor health
and health outcomes whereas increased HRV has been associated with better
health outcomes. Veterans have suffered disproportionately relative to the general
population. Veterans have worse health outcomes, report more pain, and use more
pain medication relative to the general population. Veterans have worse cognitive
performance, depression, stress, and fatigue relative to the general population.
HRVB has been shown to improve HRV, both in the general population and in
veterans, and HRVB has been shown to improve health outcomes. Results from
this analysis provide evidence that HRVB can improve HRV, decrease pain
severity and interference, reduce the number of non-steroidal anti-inflammatory
drugs used, decrease reaction time, and decrease depression.
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CHAPTER 3
METHODS AND MATERIALS
Project Design
This study was a randomized sham-controlled pilot intervention trial using a
standardized HRVB protocol for the intervention group and a sham condition for
the control group of chronic pain patients over a 16-week intervention period. This
study was approved by the WJB Dorn Veteran’s Administration Institutional
Review Board as well as the University of South Carolina Institutional Review
Board. The study was funded by the Veterans Affairs Office of Research and
Development (Grant number: I01BX007080) and was registered as a clinical trial
(NCT 02426476).
The design of this study included four assessments over a 16-week period
(Appendix A, Figure A1). The initial visit included informed consent as well as a
Baseline Assessment that included depression, stress, and fatigue questionnaire
data, a 15-minute resting HRV recording, computer-based cognitive assessments,
and saliva sample collection. Upon completion of informed consent, participants
were randomized into one of two groups: HRVB intervention group or a control
group. Each participant returned for weekly training visits over a period of six
weeks. Participants returned on week seven for a Post-training Assessment which

23

repeated the same measurements as the Baseline Assessment. A month later,
participants returned for a booster training session and a third assessment. This
Booster Assessment included the same questionnaire data and a 15-minute
resting HRV recording. The fourth and final assessment was one month after the
booster, at week 16. This final Follow-up Assessment repeated the same
questionnaire, HRV recording, cognitive assessment, and saliva collection as the
first two assessments (Appendix Figure A.1.).
Study Population
The target population consisted of veteran patients attending the WJB Dorn
Veterans Administration Medical Center (DVAMC) who were: English literate, ≥18
years old, of any race, ethnicity, or sex who met other inclusion and exclusion
criteria. Patients were recruited initially from the Dorn VAMC Pain Clinic and later
from other clinics such as Rehabilitative Medicine, Rheumatology, Primary Care,
and Physical Therapy. IRB approved brochures along with flyers were placed in
approved public areas around DVAMC so that volunteers could contact research
coordinators. The results presented in this dissertation represent data from a
preliminary sample of study participants collected from June 2016 to February
2019. Eligibility was checked using a telephone screen when the veteran
expressed interest in participation in the study. A chronic pain screen was
performed using the Pain Screening Questionnaire (Vanderbilt University Medical
Center, Center for Quality Aging, Nashville, TN). Pain was assessed with the
following questions: 1.) Do you have pain anywhere right now? 2.) Does pain ever
keep you from sleeping at night? 3.) Does your pain ever keep you from
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participating in activities/doing things you enjoy? 4.) Do you have pain every day?
If a caller identified “yes” to questions 1-3 or to question 4, then they were
determined to have chronic pain. Further eligibility was checked through VA
medical records.
Exclusions targeted medications or medical conditions that could potentially
bias measures of HRV or the outcomes, or conditions that would preclude protocol
compliance. The following exclusion criteria (assessed by self-report and medical
record review) were applied: a) history of arrhythmias requiring medication and/or
hospitalization, including supraventricular tachycardia or atrial fibrillation; b)
Veterans with a pacemaker or automatic implantable cardioverter-defibrillator; c)
history of an acute coronary syndrome, revascularization, thrombolytic or other
therapy related to ischemic heart disease; d) uncontrolled hypertension (systolic
blood pressure >140 mmHg, diastolic blood pressure >90 mmHg), however those
with well-controlled hypertension with no change in medication in six months were
not excluded; e) history of heart transplant or cardiovascular surgery within one
year; f) receiving beta-adrenergic antagonists (beta-blockers); g) receiving nondihydropyridine calcium channel blockers; h) those receiving a renin-angiotensinaldosterone system antagonist were eligible if medication profile and blood
pressure were stable; i) New York Heart Association class 3 or 4 congestive heart
failure; j) history of seizure disorder or use of antiseizure or anticonvulsant
medication; k) cognitive impairment such as dementia, or a history of acquired
neurocognitive deficit, or central nervous system or neurological disorder (e.g.,
Gulf War Syndrome); l) moderate or severe head injury or stroke; m) evidence of
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active substance abuse or dependence (alcohol or tobacco use was not an
exclusion and this data was collected during the questionnaire); n) life history of
bipolar, psychotic, panic or obsessive-compulsive disorder (history of depression
was not an exclusion).
Upon enrollment, participants signed informed consent and a Health
Insurance Portability and Accountability Act (HIPAA) medical release which were
kept on file and a copy was provided to the participant with instructions on how to
disenroll or contact the Prinicpal Investigator (PI) should they choose to do so. A
remuneration of $20 per visit was provided ($200 for completing the protocol).
Later, to increase recruitment and retention, supplement funding was provided
which included $30 per visit and $10 for travel ($400 max for completing the study).
Randomization
Assignment to either the HRVB treatment or control group was conducted
using a permuted block randomization procedure with a block size of 4 and without
stratification prior to Baseline Assessment. For example, in each block,
permutations could result in six different combinations such as 1-1-2-2, 1-2-2-1, 12-1-2, 2-1-2-1, 2-2-1-1, or 2-1-1-2. The treatment assignment was determined
before anyone was enrolled and placed in each enrollment packet where it was
kept in a confidential location. This was a single-blind study in which only the HRVB
trainer knew the group assignment of each participant. Participants were blinded
to their group assignment. At the completion of the Follow-up Assessment, those
in the control group were made aware that they had not received the intervention

26

and were offered a single “cross-over training” as an unpaid training visit to receive
the HRVB training just as the intervention group.
Intervention Group Training
HRVB training was conducted by a certified trainer following a previously
established, standardized protocol adopted by the Biofeedback Certification
Institute of America (BCIA).4, 181 Participants in the Intervention group completed a
Baseline Assessment followed by six weekly training sessions. HRVB training was
provided by a trainer on a dual-screen in which both the trainer and the participant
could visual HRVB changes in real-time. The trainer informed participants about
the connection between resonant frequency breathing and heart rate which was
reinforced with coaching to find the resonant frequency of breathing. Each weekly
HRVB training session consisted of a 25-minute resting period that included
coaching and biofeedback training. Participants were encouraged to “relax” during
their training sessions, without using their cell phones or falling asleep. HRVB
training involved two main components. The first was to assist the participant to
paint a positive mental image of something that truly makes them happy and guide
their thoughts to a peaceful, reduced-stress environment. The next portion of the
training included instruction to adjust breathing rate and pattern. Participants were
taught to perform “belly-breathing” using diaphragmatic breathing, allowing the
abdomen to distend to allow for the full use of the diaphragm. Participants were
taught to breathe deeply in through the nose and out through pursed lips, using
the diaphragm and belly in a manner that the shoulders do not rise and fall. The
use of good posture without slouching and the use of transitioning breathing
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between the peak and valley of each breath (inhalation and exhalation) were
taught. The trainer coached the participants to slow their breaths to about six
breaths per minute, allowing for the synchronization of heart rate oscillations with
respiration. This allowed the participant to achieve a state of “HRV coherence”.
This state could be directly observed on the biofeedback computer monitor by the
participant and the biofeedback coach. The synchronization of the heart rate and
breathing was observed as an increase of heart rate oscillations during inhalation
and a decrease in heart rate oscillations during exhalation. This is also referred to
as zero phase between heart rate and breathing.
For home practice, participants were provided a portable plethysmograph
(emWave2® hand-held personal stress reliever, HeartMath, Boulder Creek, CA) or
the use of a mobile-application (app) for smart phones (InnerBalance®) of their
preference for home practice and use between weekly HRVB training sessions.
Participants were encouraged to use this device for at least 15 minutes per day
between each weekly training session. Participants were instructed to use the
device at times of high-stress such as frustration, when preparing for sleep, or
simply when time was available each day. During subsequent training visits,
participants were asked how many minutes they practiced on average each day
and this self-reported information was documented, and files summarizing practice
time were downloaded from the portable emWave and mobile phone app for later
analysis.
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Intervention Group Assessments
Four assessments were made. The first was during the baseline visit. The
Post-training Assessment was conducted during the 8th week, the Booster
Assessment was conducted in the 12th week, and the Follow-up Assessment in
week 16. Questionnaire data was obtained first. Next, while participants were
seated in a comfortable position, HRV measurements were conducted over a 15minute resting period using non-stimulating nature scenes without any text, images
would change every 40 seconds as participants practiced focusing their attention,
resonant frequency breathing, and positive imagery. Third, cognitive testing was
conducted followed by saliva collection.
Control Group Training
To control for the laboratory environment or other potential placebo effects,
control group participants used the very same training equipment as the
intervention group however without any HRVB training. During the weekly training
clinic visits, control participants had HRV and respirations recorded for 15 minutes,
but no active training, coaching, or biofeedback was provided. Neither heart rate
nor breathing information was displayed on the monitor during the control group
sessions. Participants were instructed to “relax” without using cell phone or falling
asleep. Control-group participants were provided with a stress-squeeze ball to use
for home practice. They were encouraged to practice relaxing at home daily for at
least 15 minutes and encouraged to use the issued stress-ball while relaxing.
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Control Group Assessments
Control group participants attended the same four Baseline, Post-training,
Booster, and Follow-up Assessments with the time separation and duration as the
intervention participants. Questionnaire data was collected. During the passive 15minute HRV recording period, subjects viewed the same static, relaxing nature
scenes on the computer monitor as were presented to the HRVB intervention
group for assessments. They sat quietly while passively observing non-stimulating
nature scenes without any text. These images changed every 40 seconds.
Cognitive tests were conducted followed by saliva collection.
HRV Outcomes
Each resting HRV outcome was measured at the four assessments
(Baseline, Post-training, Booster, and Follow-up) in a standardized manner. HRV
recording was conducted in an office setting with dimmed lights. Nature slides were
viewed at each of the assessments during the recording. At baseline, the
participants were asked to relax. At subsequent assessments, the participants in
the HRVB group were instructed “Do what you have been trained to do”. No other
instructions or biofeedback was provided. HRV data was collected with two
electrodes to the left forearm and one to the right. Respirations were monitored
using a Piezo-respiratory transducer. Both groups completed a 15-minute resting
HRV recording with an Acquire ECG encoder.
Inter-Beat Intervals (IBI) files were exported and processed according to
established guidelines (Appendix A, Figure A.2).182 Kubios software (Kuopio,
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Finland) was used to de-artifact raw data and perform a fast Fourier transformation
of the HRV power spectrum for each data file. Time-domain HRV measures: mean
heart rate, SDNN (standard deviation of heart rate N-N intervals) 54, RMSSD (the
square root of the mean squared difference of successive N-N intervals), and
frequency-domain variables: (Very Low Frequency (VLF), Low Frequency (LF),
High Frequency (HF) power, Total Power, and Coherence Ratio) were calculated.
The HRV coherence ratio was obtained by identifying the maximum peak in the
0.04 Hz to 0.26 Hz HRV range, calculating the integral in a window 0.030 Hz wide
centered on the highest peak in that region (‘peak power’, usually ~0.1 Hz), then
calculating the total power of the entire spectrum. The HRV Coherence Ratio (as
described by McCraty) was quantified as: peak power / (total power – peak power).
The frequency range of 0.04-0.26 Hz was selected because it is the range within
which HRV coherence (i.e. cardiorespiratory entrainment) occurs.7, 8, 58, 66
Questionnaire Outcomes
A structured, self-administered questionnaire was used to obtain
sociodemographic (age, race, ethnicity, sex, body mass index, education, income,
marital status), and lifestyle information (pain medication use, alcohol, caffeine
consumption, tobacco use, circadian preference, employment status) (Appendix
Figure A.3.). Information obtained from the patient’s medical record included
chronic pain condition with diagnosis. Symptoms of: pain (BPI),183, 184 depression
(BDI),185 stress (PSS),186 and fatigue (MFI),170,

172

were obtained at all four

assessments. Higher scores on each symptom questionnaire corresponded to
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increased symptom severity. Symptoms were scored in accordance with the
original documentation accompanying each instrument.
Pain Outcomes
Pain was assessed using two instruments: Brief Pain Inventory (BPI)184 and
the Pain Catastrophizing Score (PCS).187 Originally the BPI was designed for
cancer patients by the World Health Organization and has since been used in
many research and clinic settings.183, 188 The BPI has been used for its reliability
and validity in many languages and used in pain studies.183, 188 The Brief Pain
Index has been validated as an effective gauge for those who have pain related to
malignant and nonmalignant disorders.184, 189 This self-reported questionnaire for
pain severity ranges with a pain-free score of 0 to worst pain of 10. Reliability and
validity have been demonstrated.183,

190-192

Negative emotion and physical

inactivity are subscales of the BPI.193 Pain interference was evaluated using the
BPI with a scale of 0-10 in which 0 is no interference and 10 complete
interference.184, 194
Pain was also assessed using the PCS.187 The PCS explores factors that
impact pain through catastrophizing, was developed from literature for catastrophic
thinking as it relates to experiencing pain, is written at the sixth-grade level and
performed in 5 minutes or less. Thirteen items are summed to provide a total score
for the PCS with a range from 0-52. After reflecting on painful experiences, the
PCS provides three subscales to assess helplessness, magnification of problems
and pain, and rumination. The PCS has been shown to have internal consistency
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with alpha coefficients for total PCS 0.87, rumination 0.87, magnification 0.66, and
helplessness 0.78.187
Cognitive Outcomes
The PASAT is used to assess processing speed, attention, working memory
and is influenced by fatigue195. Strongly correlated with education, PASAT has
demonstrated repeatability and tends to decrease score with increased age195.
Standardized options for PASAT exist with 29, 50, or 60 summed pairs195,

196.

Spoken at three second intervals from a recording, numbers were read aloud. The
participant summed the last two spoken numbers provided by the researcher. The
total score of correct responses was summed for a maximum score of 29.
The Hopkins Verbal Learning Test-Revised (HVLT-R) is a tool used to
measure verbal and working memory as well as executive functioning through
immediate and delayed recall of terms.197 HVLT utilizes a list of words that the
participant hears and then repeats when all 12 have been provided verbally. It is
scored on a scale of 0-36 in which 0 indicates no correct responses and 36 is the
max in which all responses were correct.197 As noted, the list of words has three
themes such as items of clothing, tools, occupations, etc., heard three separate
times. At each of the three assessments (Baseline, Post-training, and Follow-Up),
the participant is provided a different set of words to recall after hearing them.
Visualization of the words is not provided. This test can ascertain immediate recall
from an auditory stimulus.

33

The Psychomotor Vigilance Test (PVT) is a 10-minute timed test in which a
participant reacts to a stimulus on a computer screen. The stimulus varies in time
between 2-10 seconds in between the stimuli. The red dot remains on the screen
for 1 second198 and the reaction time is measured in milliseconds. The shorter the
reaction time, the faster the response. A response time more than 500ms is a lapse
or missed response which may be suggestive of sleep deprivation or inability to
sustain concentration.
Depression, Stress, & Fatigue Outcomes
Depression was measured using the Beck Depression Inventory-II (BDI).
BDI was established by Beck et al. in the 1960s referencing many psychological
publications of the time.199 This was updated in 1978 as the BDI-IA200, 201 and in
1996 as the Beck Depression Inventory-II.200, 201 Normative variables have been
established for male military veterans with chronic pain which may assist in
assessing those who have more physical complaints than what is considered to
be normal and possibly decrease confounding.201 The BDI is a 21-item selfreported questionnaire to elucidate the severity of depression experienced by the
reporter following diagnostic criteria established in 1994 by the Diagnostic and
Statistical Manual of Mental Disorders (4th Edition) (DSM-IV).201

Cutoffs have

been standardized: 0–9 indicates normal, 10–18 indicates mild depression, 19–29
indicates moderate depression, and 30–63 indicates severe depression.202,

203

This test has excellent reliability (Cronbach alpha:0.92),185 and has been validated
to separate depressed from non-depressed individuals.204 Reported levels in
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depression/mood were assessed at each of the four previously stated
assessments through the use of the BDI-II.
Stress was evaluated using the Perceived Stress Scale (PSS).26, 186 This
tool was first developed in 1983186 has since been adapted for participants to
answer questions in a way that causes them to consider different aspects of their
lives and qualify how stressful and messy they feel their lives may be. Once a 14item questionnaire, this questionnaire now has a 10-item negative and 4-item
positive component. PSS is a self-reported questionnaire where individuals can
rate their stress. Reliability and validity have been demonstrated.79, 186, 205 Each
question is based on a 5-point score ranging from (0) to (4) or “never” to “very
often”.

206

The PSS has been widely used and has been validated in numerous

languages and populations. It presents data representing the degree to which the
participant feels out-of-control, feels life is unpredictable, and feels overloaded by
external factors.186 Seven positive items are reverse-scored and then all questions
are summed.

186

Reported levels in perceived stress were assessed through the

PSS at each of the four previously stated time assessments.
Fatigue was assessed using the Multi-dimensional Fatigue Inventory (MFI).
The MFI provides insight to motivation, physical activity, mental and general
fatigue. Its 20 questions have demonstrated internal consistency and external
validity.170,

172

Changes in fatigue and energy level were assessed exploring

differences in the MFI at each of the previously stated four assessments.
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Statistical Analysis
All statistical analyses were performed using SAS 9.4 (SAS Institute. Inc.,
Cary NC.) Descriptive characteristics of participants were summarized between
intervention and control groups. Analysis included demographic and lifestyle
variables comparing between groups using the Student t test for normally
distributed continuous variables, the Wilcoxon exact test for non-normally
distributed continuous variables or Fisher’s exact test of independence for discreet
variables. Continuous outcomes were compared between groups. To compare the
main outcomes of interest (HRV coherence, PS, PIS, PCS, pain medication usage,
PASAT, HVLT, PVT, BDI, PSS, and MFI) with group, time, and group by time
interaction, linear mixed models were utilized after adjusting for demographics
and/or lifestyle variables.
The process of randomization reduces the possibility of confounding
between groups. To ensure this was effective, potential confounders were
evaluated to determine if they were equally distributed among the intervention and
the control groups. While randomization should remove potential confounding
variables, demographic characteristics and outcomes measures were evaluated
using bivariate comparisons between the two groups. Comparisons of categorical
variables such as gender, race, and income were made between groups of
baseline sociodemographic, comorbid health diagnoses, and lifestyle choices
using Fisher’s Exact test (PROC FREQ in SAS). Due to small cell counts,
American Indian and Other races were combined with African American into one
category named “Minorities”. Normality of distribution of continuous variables such
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as age were evaluated (PROC UNIVARIATE in SAS). As depression can impact
other variables such as pain, the BDI was considered a priori as a possible
confounder for pain outcomes.
To be included in the study, baseline characteristics had to be provided by
participants, resulting in limited missing baseline data. Missing data was assumed
to be missing-at-random and was therefore ignored. Variables in which less than
10% of the population contributed to one category were removed from the analysis.
No veterans in this study were prescribed stimulant medication at baseline and
therefore this was not included in the analysis. Sleep apnea was also not
diagnosed among participants in this study at baseline and was not included in the
analysis. Medication type and frequency of usage was provided by the participant
in each of the assessment questionnaires. The following medication classes were
included in the analysis: non-steroidal anti-inflammatory drugs (NSAIDs), opioids,
over-the-counter pain medications (OTC), musculoskeletal relaxants, sleep aids
(sedatives, hypnotics), anxiolytics, and anti-depressants. None of the medications
were normally distributed at baseline and therefore were logged and then back
transformed for interpretability. The following comorbid diagnosis were found at
baseline and included in the analysis: hypertension (HTN), cancer, depression,
anxiety, post-traumatic stress disorder (PTSD), chronic headaches, diabetes,
metabolic syndrome, and chronic fatigue. These data were gathered from DAVMC
medical records.
A repeated measures mixed effects model (PROC MIXED in SAS) was
used to evaluate the effects of group (HRVB vs. sham), time, and group by time
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interaction. The following covariance matrices were considered: unstructured
(UN), compound symmetric (CS), and heterogeneous compound symmetric (CSH)
and the smallest Akaike Information Criterion (AIC) was selected for the final
model. In the HRVB intervention group, one-tailed p-values were used for a priori
directional hypotheses to determine the effectiveness of the HRVB intervention.
Based on previous literature, the benefit of HRVB was expected to demonstrate
positive effects and a directional change, therefore statistical significance was
assessed utilizing one-tailed p-values to interpret results for specific comparisons
in the intervention group. As there was no beneficial effect expected in the control
group, the use of a priori directional hypotheses were not employed and were
reported using two-tailed p-values. Pre-determined contrasts were made
comparing Baseline Assessment with the Post-training Assessment, and Followup Assessment. To assess treatment sustainability, the Post-training Assessment
data were compared to the Follow-up Assessment. If baseline variables were
statistically significantly different (p<0.05), then they were considered as possible
confounders. Differing baseline demographic covariates were kept in the final
model when the parameter estimates changed by ≥10%. This was applied until all
statistically significant differing baseline covariates were checked. Statistically
significant covariates were retained in the model without regard to the effect of the
parameter estimate.
HRV was compared between groups and assessments using least square
(LS) means for the following HRV measures: SDNN, RMSSD, VLF power, LF
power, HF power, and HRV Coherence Ratio. Normality was checked using PROC

38

UNIVARIATE. As the HRV variables were not normally distributed at baseline,
each variable was logged and then back transformed for interpretability. HRV
Coherence Ratio was calculated as previously cited by McCraty.7 In the linear
mixed model, with group, time, group by time interaction, the best (lowest) AIC was
found using the unstructured (UN) matrix. For the SDNN and RMSSD outcome,
the same linear mixed model was used using the heterogeneous compound
symmetry (CSH) covariance matrix as it provided the best AIC. For the VLF
outcome, the same linear mixed model was used using the UN matrix. And for the
LF and HF outcomes, the same linear mixed model was used using compound
symmetry (CS) matrix. Results were back-transformed from the logged LS Means
Estimates.
Outcomes for all pain variables (PS, PIS, and PCS) were reported using
LS Means Estimates using the already described linear mixed model above. The
PS outcome was reported using the CSH covariance matrix as it provided the best
AIC while adjusting for depression and race. The PIS outcome was reported using
the CSH covariance matrix as it provided the best AIC while adjusting for pain
interference as PIS was different between groups at baseline. PCS outcome was
reported using the CS covariance matrix as it provided the best AIC while adjusting
for depression.
The following pain medication variables were assessed: NSAIDs (i.e.
piroxicam, meloxicam), opioids (i.e. morphine, oxycodone), OTC (i.e. aspirin, BC
powder), musculoskeletal relaxants (i.e. cyclobenzaprine, methocarbamol), sleep
aids (i.e. zolpidem, eszopiclone), anxiolytics (i.e. diazepam, alprazolam), and anti-
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depressants (i.e. fluoxetine, paroxetine). None of the pain medication was normally
distributed at baseline when assessing using Proc Univariate. All reported
medications were log transformed and then back-transformed for interpretability
using the same linear mixed model already described. All medication results were
reported as the back-transformed logged LS Means Estimates. NSAID outcomes
were found to have the best AIC using the CSH covariance matrix. Opioid, OTC,
sedatives, musculoskeletal, sleep, and anti-anxiety medications were found to
have the best AIC using the CS covariance matrix. Anti-depressant medication
outcomes were found to have the best AIC using the UN covariance matrix.
For cognitive outcomes, PASAT and HVLT were assessed using the same
linear mixed model, reported as LS Means Estimates, and were found to have the
best AIC using the CS matrix while adjusting for race. For the PVT cognitive
outcomes (reaction time and lapses), in a review of literature, due to wide ranging
results with the mean or median reaction time, multiple authors have
recommended using the reciprocal of the mean reaction time.207-209 Emphasis was
placed on the reciprocal of the mean reaction time. Outcomes of the reciprocal
mean reaction time were assessed utilizing the same linear mixed models as
described above with LS Means Estimates. The best AIC was found using the CSH
covariance matrix while adjusting for race and then back-transformed for
interpretability. As the number of lapses were not normally distributed, the number
of lapses were log transformed using LS Means Estimates and then backtransformed for interpretability. The best AIC was found using the UN covariance
matrix while adjusting for race.
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Depression (BDI) outcome was analyzed using the already established
linear mixed model and reported using LS Means Estimates. The best AIC was
found using the CS covariance matrix while adjusting for baseline depression as
they were different between groups at baseline. Stress (PSS) outcome was
reported using LS Means Estimates and the best AIC was found using the CSH
covariance matrix while adjusting for race and depression. Fatigue (MFI) outcomes
were reported using the five subcomponents of fatigue using LS Means Estimates
from the already described linear mixed model. General fatigue was reported with
the best AIC found using the CS covariance matrix while adjusting for race. Mental
fatigue was found to have the best AIC with the CS matrix while adjusting for
depression. Physical fatigue was found to have the best AIC using the CS matrix
while adjusting for race. Reduced activity was found to have the best AIC using
the CS matrix while adjusting for race and pain. Reduced motivation was found to
have the best AIC using the CS matrix while adjusting for pain.
To test the effect size of the change in outcome measurements between
Baseline to Post-training Assessment and Baseline to Follow-up Assessment,
Cohen’s D was calculated using the following formula: Cohen’s D = (M2M1)/SDpooled.
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CHAPTER 4
RESULTS
4.1 Overall Characteristic Results
A total of 85 United States military veterans were enrolled in the study, 63
completed the Post-training Assessment, 54 achieved the Booster Assessment,
and 50 accomplished the Follow-up Assessment (59% completion). Attrition by
intervention group demonstrated no statistically significant differences (Figure A.4,
Consort Flow Diagram). Demographic (Table 4.1) and comorbid variables (Table
4.2) at baseline are displayed. Most demographic characteristics were equally
proportioned. Participants were mostly male (66%), college educated (73%), and
non-smokers (85%) (Table 4.1). Age was similar between groups; the average age
(± standard error of the mean) for the HRVB intervention group was 54 ± 11 years
and was 55 ± 12 in the control group. Race was the only baseline characteristic
that exhibited statistically significant differences between groups (Caucasian: 37%
in intervention vs 63% in control group, p=0.04, Table 4.1). Race was viewed as a
potential confounder and considered as such in the statistical analyses. The
amount of time it took for participants to complete this study due to cancellation of
appointments or rescheduling was evaluated within both groups.
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With no missed appointments or rescheduling, the study should have been
completed in 112 days. Completion of the study protocol took on average 123 ±
21 days and no statistically significant differences were observed between groups
among protocol completers (124 days for intervention group, 121 days for control
group, p=0.54, Table 4.1).

Evaluation of medical records at baseline was

conducted of comorbid diagnoses as possible confounders (Table 4.2) however
there were no statistically significant differences in comorbid diseases between the
groups. Baseline scores for pain interference, depression (BDI), and race were
statistically significantly different between groups. Further analysis was conducted
among those who completed the study relative to those who were lost-to-follow-up
(LTF). Of the 85 participants in the study, 9 were still active at the time of this
analysis, 50 completed the study, and 26 were LTF. The 9 active participants were
removed from completion status analysis. Among those who completed the study,
the average age in years was 57±9.9 compared to those who were LTF were
50±11.6 (p=0.01, Table 4.14). No other differences in demographics or
comorbidities were found between those who completed the study and those who
were LTF.
4.2 HRV Results
Least Square Means (LS Means) HRV Coherence Ratios increased
between baseline and post-training within the intervention group (0.17 ± 0.02 at
baseline versus 0.41 ± 0.07 at post-training, p=<0.01, Table 4.3) and between
post-training and follow-up with in the intervention group (0.41 ± 0.07 at posttraining versus 0.45 ± 0.08 at follow-up, p=<0.03). The control group did not exhibit
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any improvement between baseline and post-training (0.17 at baseline versus 0.18
post-training, p=0.61) nor post-training to follow-up (0.18 at post-training versus
0.18 at follow-up, p=0.94). Statistical significance was found in the group by
timepoint interaction for the HRV Coherence Ratio (p=<0.01). LS Means HRV
Coherence Ratios in the intervention group also were elevated at follow-up relative
to baseline (0.17 ± 0.02 at baseline versus 0.45 ± 0.08 at follow-up, p=<0.01, Table
4.4). Figure 4.1 displays the HRV Coherence Ratio for each of the timepoints.
LS Means SDNN was found to increase in both groups between baseline
and post-training and only in the control group between baseline and follow-up.
RMSSD and VLF increased only in the control group between baseline and posttraining (Tables 4.3 and 4.4). LF increased in both groups when comparing posttraining and follow-up to baseline (Figure 4.2) (Tables 4.3 and 4.4). HF increased
in the control group from baseline to post-training (Tables 4.3 and 4.4).
4.3 Pain Results
Decreases in PS were observed among the intervention group while
adjusting for race and depression with a reduction at post-training as compared to
baseline (5.67 ± 0.25 at baseline versus 5.24 ± 0.27 at post-training, p=0.023,
Table 4.5) and decreases were also observed between Baseline and Follow-up
Assessment (5.67 ± 0.25 at baseline versus 5.13 ± 0.31 at follow-up, p=0.03, Table
4.6). The group by time interaction also revealed statistically significant findings,
p=0.04 (Tables 4.5 and 4.6) and displayed in Figure 4.3.
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Baseline scores for pain interference were statistically significantly different
between groups. Decreases in PIS were observed among the intervention group
while adjusting for pain at baseline with a reduction at post-training as compared
to baseline (5.67 ± 0.19 at baseline versus 4.74 ± 0.24 at post-training, p=<0.01,
Table 4.5) and decreases were also observed between Baseline and Follow-up
Assessment (5.67 ± 0.19 at baseline versus 4.69 ± 0.37 at follow-up, p=<0.01,
Table 4.6). The group by time interaction also revealed statistically significant
findings (p=<0.01, Tables 4.5 and 4.6, Figure 4.4).
Decreases for PCS while adjusting for baseline depression were found in
both groups from baseline to post-training and baseline follow-up: intervention
group (25.56 ± 1.64 at baseline versus at post-training 22.69 ± 1.8, p=0.01 , Table
4.5) and (25.56 ± 1.64 at baseline versus at follow-up 21.00± 1.84, p=<0.01, Table
4.6) whereas for the control group (28.06 ± 1.71 at baseline versus 24.44 ± 1.80
at post-training , p=<0.01 , Table 4.5) and (28.06 ± 1.71 at baseline versus 23.87
± 1.88 at follow-up, p=<0.01, Table 4.6) However, there was not a statistically
significant group by time interaction observed (p=0.58, Table 4.6) and displayed in
Figure 4.5.
Reductions in pain medication use were found in NSAIDS for the
Intervention group at baseline compared to follow-up and reported in log backtransformed LS Means Estimates (1.35 ± 0.10 at baseline versus 1.12 ± 0.10 at
follow-up, p=0.02, Tables 4.7 and 4.8) however was not observed in the group by
time interaction (p=0.08, Table 4.8). Results for NSAID use are displayed in Figure
4.6 and for opioid use in Figure 4.7.
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4.4 Cognitive Results
Increases for PASAT score after adjusting for race at baseline were seen in
both groups between baseline and follow-up: intervention group (16.9 ± 1.09 at
baseline versus 20.29 ± 1.21 at follow-up, p=<0.01, Table 4.10) and control group
(18.52 ± 1.07 at baseline versus 21.06 ± 1.14 at follow-up, p=0.01, Table 4.10).
There was not a statistically significant group by time interaction observed (p=0.16,
Table 4.10). PASAT is displayed in Figure 4.8.
Increases for HVLT after adjusting for race at baseline were seen in both
groups between baseline and follow-up: intervention group (23.82 ± 0.79 at
baseline versus 26.19 ± 0.93 at follow-up, p=<0.01, Table 4.10) and control group
(23.92 ± 0.78 at baseline versus 26.84 ± 0.86 at follow-up, p=<0.01, Table 4.10).
However, there was not a statistically significant group by time interaction
observed (p=0.89, Table 4.10). HVLT is displayed in Figure 4.9.
Decrease in the back-transformed reciprocal mean reaction time while
adjusting for race at baseline was observed in the intervention group between
baseline and follow-up (431.59± 17.32 at baseline versus 407.50 ± 17.71 at followup, p=0.04, Table 4.10). However, there was not a statistically significant group by
time interaction observed (p=0.90, Table 4.10). Reaction time is displayed in
Figure 4.10.
Decrease in the back-transformed logged number of lapses while adjusting
for race at baseline were seen in both groups between baseline and follow-up:
intervention group (9.056 ± 1.16 at baseline versus 6.05 ± 1.19 at follow-up,
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p=<0.01, Table 4.10) and control group (9.054 ± 1.16 at baseline versus 6.46 ±
1.18 at follow-up, p=0.01, Table 4.10). However, there was not a statistically
significant group by time interaction observed (p=0.79, Table 4.10). Number of
lapses is displayed in Figure 4.11.
4.5 Depression, Stress, and Fatigue Results
Baseline scores for depression (BDI) were statistically significantly different
between groups. Decrease in the BDI while adjusting for depression at baseline
was found in the intervention group from baseline and post-training (21.9 ± 1.04 at
baseline versus 17.66 ± 1.22 at post-training, p=<0.01, Table 4.11) and baseline
to follow-up (21.9 ± 1.04 at baseline versus 16.30 ± 1.34 at follow-up, p=<0.01,
Table 4.12). There was a statistically significant group by time interaction observed
(p=0.03, Table 4.12). BDI is displayed in Figure 4.12.
PSS did not result in any statistically significant results while adjusting for
baseline depression for either group when comparing baseline to post-training and
when comparing baseline to follow-up (Tables 4.11 and 4.12). There was no
statistically significant group by time interaction observed (p=0.76, 4.12). PSS is
displayed in Figure 4.13.
Adjustments were made for the five categories of fatigue: General fatigue
was adjusted for baseline race, mental fatigue was adjusted for baseline
depression, physical fatigue was adjusted for baseline race, reduced activity was
adjusted for baseline race and pain, and reduced motivation was adjusted for
baseline pain. Among all of these, there were no statistically significant
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improvements for either group and no statistically significant group by time
interactions. However, for the control group, there was a reported worsening of
symptoms in physical fatigue with an increase from baseline to post-training (12.42
± 0.31 at baseline versus 13.39 ± 0.35 at post-training, p=0.02, Table 4.11).
General fatigue (Figure 4.14), mental fatigue (Figure 4.15), physical fatigue (Figure
4.16), reduced activity (Figure 4.17), and reduced motivation (Figure 4.18) are
displayed.
Post-hoc analysis was conducted as concern for possible over-adjusting of
baseline differences of dependent variable outcomes. For example, both
depression and pain interference differed at baseline and were originally adjusted
in the linear mixed models. When using the CSH matrix, pain interference was
reanalyzed using a linear mixed model without adjusting for baseline differences.
In the intervention group, comparing baseline to post-training (6.95 ± 0.35 at
baseline vs 6.05 ± 0.40 post-training, p=<0.01) and baseline to follow-up (6.95 ±
0.35 at baseline vs 5.95 ± 0.46, p=<0.01) and in the control group comparing
baseline to post-training (5.95 ± 0.36 at baseline vs 5.69 ± 0.40 post-training,
p=0.39) and baseline to follow-up (5.95 ± 0.36 at baseline vs 5.76 ± 0.46, p=0.58).
Further analyses were performed for unadjusted depression using a CS
matrix and a linear mixed model without adjusting for baseline differences. In the
intervention group comparing baseline to post-training (23.95 ± 1.91 at baseline vs
20.09 ± 2.05 post-training, p=<0.01) and baseline to follow-up (23.95 ± 1.91 at
baseline vs 18.59 ± 2.13 at follow-up, p=<0.01) and in the control group comparing
baseline to post-training (18.41 ± 1.97 at baseline vs 18.20 ± 2.07 post-training,
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p=0.88) and baseline to follow-up (18.41 ± 1.97 at baseline vs 17.35 ± 2.17,
p=0.49).
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Table 4.1. Demographics
Total (n=85)

HRVB (n=44)

Age (years± SD)
Gender
n (%)
F (%)
M (%)
Race
Minorities (%)
Caucasian (%)
Education

54 ± 11

54 ± 11

Control
(n=41)
55 ± 12

28 (33)
56(66)

15(34)
29 (66)

13 (32)
27 (66)

53 (62)
32 (38)

32 (73)
12 (27)

21 (51)
20 (49)

Less Than
College
College
Graduate
School
Income
Under $30,000
$30,000-50,000
$50,001 or more
Refused
Don’t know
Current Smoke
Yes
No
Smoke
Cigarette Ever
Yes
No
Don’t Know
Missing
Study
Completion in
Days ± SD

23 (27)

10 (23)

13 (32)

51 (60)
11 (13)

28 (63)
6 (14)

23 (56)
5 (12)

33 (39)
17 (20)
30 (35)
4 (5)
1 (1)

15 (34)
8 (18)
18 (41)
2 (5)
1 (2)

18 (44)
9 (22)
12 (29)
2 (5)
0 (0)

13 (15)
72 (85)

6 (14)
38 (86)

7 (17)
34 (83)

p-value
0.65
0.57
0.04
0.65

0.66

0.66
0.63

35 (41)
45 (53)
1 (1)
4
123 ± 21

18 (41)
24 (55)
1 (2)
1 (2)
124 ± 18

17 (41)
21 (51)
0 (0)
2
121 ± 23

0.54

Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for
categorical variables. Pooled T-test used for continuous variables. F: Female. M:
Male. SD: Standard Deviation. Study Completion in Days: Total days to complete
study from Baseline visit to completion of Follow-up Assessment.
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Table 4.2. Comorbidities at Baseline by Group
Overall
(n=85)
Hypertension
Yes (%)
No (%)
Cancer
Yes (%)
No (%)
Depression
Yes (%)
No (%)
Anxiety
Yes (%)
No (%)
PTSD
Yes (%)
No (%)
Diabetes
Yes (%)
No (%)

Intervention
(n=44)

Control
(n=41)

p-value
0.38

38 (45)
47 (55)

22 (50)
22 (50)

16 (39)
25 (61)

8 (9)
77 (91)

4 (9)
40 (91)

4 (10)
37 (90)

0.92

0.91
42 (49)
43 (51)

22 (50)
22 (50)

20 (49)
21 (51)

19 (22)
66 (78)

12 (27)
32 (73)

7 (17)
34 (83)

0.26

0.98
31 (36)
54 (64)

16 (36)
28 (64)

15 (37)
26 (63)

24 (28)
61 (72)

14 (32)
30 (68)

10 (24)
31 (76)

0.45

Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for
categorical variables. Pooled T-test used for continuous variables. F: Female. M:
Male. SD: Standard Deviation. Study Completion in Days: Total days to complete
study from Baseline visit to completion of Follow-up Assessment. PTSD: Post
Traumatic Stress Disorder.
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Table 4.3: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Post-training Assessments
Outcome

HRV Coherence
Ratio

SDNN

52
RMSSD

VLF Power

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-Training (T2)
Est µ± SE

n

0.17 ± 0.02

43

0.41 ± 0.07

31

B
Est A-B±SE
(t, p)

0.17 ± 0.02
0.01 ± 0.16
(0.22, 0.82a)

41

32

84

0.18 ± 0.03
0.23 ± 0.11
(3.30, <0.01b)

A

27.5 ± 2.22

43

31.7 ± 3.24

31

B
Est A-B±SE
(t, p)

27.9 ± 2.31
-0.4 ± 0.1
(0.13, 0.89a)

41

32

84

37.6 ± 3.84
-5.9 ± 0.17
(-1.18, 0.12b)

63

A

16.9 ± 1.74

43

17.2 ± 2.32

31

B
Est A-B±SE
(t, p)

16.7 ± 1.76
0.2 ± 0.11
(-0.07, 0.94a)

41
84

23.4 ± 3.16
-6.2 ± 0.26
(1.61, 0.05b)

A

265.0 ± 46.7

43

230.0 ± 46.6

31

B
Est A-B±SE
(t, p)

259.0 ± 46.9
6.0 ± 0.25
(-0.08, 0.94a)

41

429.0 ± 86.2
-199.0 ± 0.52
(-2.18, 0.02b)

32

-35.0 ± 0.24
(0.66, 0.25c)
170.0 ± 0.12
(-2.46, 0.02d)

63

n/a

84

63

Est. T2-T1±SE (t,
p)
0.24 ± 0.08
(4.59, <0.01c)
0.01 ± 0.17
(0.51, 0.61d)
n/a
4.2 ± 0.08
(-1.63, 0.05c)
9.7 ± 0.06
(-3.40, <0.01d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(20.27, <0.01)
(6.62, <0.01)
(5.95, <0.01)
(0.45, 0.51)
(4.88, <0.01)

32

n/a
0.3 ± 0.11
(-0.18, 0.43c)
6.7 ± 0.08
(-2.96, <0.01d)

(0.61, 0.61)

(1.75, 0.16)

63

n/a

(1.51, 0.21)

(0.68, 0.41)

(4.65, 0.03)
(0.86,0.46)
(4.48, <0.01)

Table 4.3: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Post-training Assessments
Outcome

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-training (T2)
Est µ± SE

Est. T2-T1±SE (t, p)
n

167.6 ± 36.8

43

442.5 ± 106

31

B
Est A-B±SE
(t, p)

170.3 ± 37.3
-2.7 ± 0.31
(-0.05, 0.96a)

41

32

84

309.4 ± 74
133.1 ± 0.24
(-1.06, 0.29b)

63

A

81.1 ± 18.8

43

70.4 ± 17.8

31

B
Est A-B±SE
(t, p)

85.1 ± 20.2
-4.0 ± 0.35
(0.15, 0.89a)

41

155.9 ± 40.1
-85.5 ± 0.81
(2.19, 0.02b)

LF Power

HF Power

53

84

274.9 ± 0.08
(-4.34, <0.01c)
139.1 ± 0.12
(-2.69, <0.01d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(1.05, 0.31)
(11.36, <0.01)
(0.77, 0.51)

32

n/a
-10.7 ± 0.27
(0.61, 0.27c)
70.8 ± 0.13
(-2.6, 0.01d)

63

n/a

(1.93, 0.13)

(1.61, 0.21)
(0.74, 0.53)

LS-Means estimates displayed as mean. Larger scores represent greater HRV Coherence SDNN: Standard Deviation of
the Normal to Normal in milliseconds (ms). RMSSD: Root Mean Square of the Successive Differences in ms. VLF Power:
Very Low Frequency Power in ms2. LF Power: Low Frequency Power in ms2. HF Power: High Frequency Power in ms2.
a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline Assessment
and Post-training Assessment. d2-sided comparison between Baseline Assessment and Post-training Assessment. µ:
Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: test statistic. p: p-value. Group x Timepoint:
Type 3 test of fixed effects for group by timepoint interaction term (1-sided).

Table 4.4: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Follow-up Assessments
Outcome

HRV Coherence
Ratio

SDNN

54
RMSSD

VLF Power

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Follow-up (T4)
Est µ± SE

n

0.17 ± 0.02

43

0.45 ± 0.08

25

B
Est A-B±SE
(t, p)

0.17 ± 0.02
0.01 ± 0.16
(-0.22, 0.82a)

41

25

84

0.19 ± 0.03
0.26 ± 0.10
(-3.75, <0.01b)

50

A

27.5 ± 2.22

43

31.1 ± 3.79

25

B
Est A-B±SE
(t, p)

27.9 ± 2.31
-0.4 ± 0.1
(0.13, 0.89a)

41

25

84

34.8 ± 4.27
-3.7 ± 0.19
(0.65, 0.26b)

A

16.9 ± 1.74

43

16.25 ± 1.93

25

B
Est A-B±SE
(t, p)

16.7 ± 1.76
0.2 ± 0.11
(-0.07, 0.94a)

41

18.96 ± 2.27
-2.71 ± 0.20
(0.91, 0.18b)

25

84

50

50

Est. T4-T1±SE (t,
p)
0.28 ± 0.07
(-5.25, <0.01c)
0.02 ± 0.16
(-0.60, 0.55d)
n/a
3.6 ± 0.09
(-1.18, 0.12c)
7 ± 0.08
(-2.09, 0.04d)

(20.27, <0.01)
(6.62, <0.01)
(5.95, <0.01)
(0.45, 0.51)
(4.88, <0.01)

n/a
-0.65 ± 0.11
(0.36, 0.36c)
2.26 ± 0.10
(-1.13, 0.26d)

(1.75, 0.16)

n/a

(1.51, 0.21)

A

265.0 ± 46.7

43

210.0 ± 55.7

25

B
Est A-B±SE
(t, p)

259.0 ± 46.9
6.0 ± 0.25
(-0.08, 0.94a)

41

408.0 ± 109
-198.0 ± 0.73
(1.77, 0.04b)

25

-54.0 ± 0.32
(0.9, 0.18c)
154.0 ± 0.16
(-1.77, 0.08d)

50

n/a

84

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)

(0.61, 0.61)
(0.68, 0.41)

(4.65, 0.03)
(0.86,0.46)
(4.48, <0.01)

Table 4.4: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Follow-up Assessments
Outcome

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A
B
Est A-B±SE
(t, p)
A

n

Post-training (T4)
Est µ± SE

Est. T4-T1±SE (t, p)
n

167.6 ± 36.8

43

427.8 ± 109.8

25

170.3 ± 37.3
-2.7 ± 0.31
(-0.05, 0.96a)

41

25

84

279.2 ± 72.1
148.6 ± 0.24
(-1.17, 0.12b)

50

81.1 ± 18.8

43

68.1 ± 18.7

25

85.1 ± 20.2
-4.0 ± 0.35
(0.15, 0.88a)

41

109.0 ± 30.1
-40.9 ±0.62
(1.21, 0.11b)

LF Power

55

Est A-B±SE
(t, p)

84

(1.05, 0.31)
(11.36, <0.01)

(1.61, 0.21)

25

n/a
-13.0 ± 0.27
(0.61, 0.27c)
23.9 ± 0.20
(-0.97, 0.33)

50

n/a

(1.93, 0.13)

B
HF Power

260.2 ± 0.09
(-3.88, <0.01c)
108.9 ± 0.15
(-2.04, 0.04d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)

(0.77, 0.51)

(0.74, 0.53)

LS-Means estimates displayed as mean. Larger scores represent greater HRV Coherence SDNN: Standard Deviation of
the Normal to Normal measured in milliseconds (ms). RMSSD: Root Mean Square of the Successive Differences in ms.
VLF Power: Very Low Frequency Power in ms2. LF Power: Low Frequency Power in ms2. HF Power: High Frequency
Power in ms2. a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline
Assessment and Follow-up Assessment. d2-sided comparison between Baseline Assessment and Follow-up Assessment.
µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: t-test statistic. f: F test statistic. p: p-value.
Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction term (1-sided).

Table 4.5: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Post-Training Assessments
Outcome

Pain Severity
Score#

Pain Interference
Score^

56
Pain
Catastrophizing
Scale*

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-Training (T2)
Est µ± SE

n

5.67 ± 0.25

44

5.24 ± 0.27

31

B
Est A-B±SE
(t, p)

5.93 ± 0.25
0.26 ± 0.36
(0.73, 0.47a)

41

32

85

5.72 ± 0.26
0.48 ± 0.38
(1.27, 0.21a)

63

A

5.67 ± 0.19

44

4.74 ± 0.24

31

B
Est A-B±SE
(t, p)

5.59 ± 0.18
-0.08 ± 0.25
(-0.31, 0.76a)

41

32

85

5.33 ± 0.23
0.59 ± 0.33
(1.81, 0.07a)

63

A

25.56 ± 1.6

44

22.69 ± 1.8

31

B
Est A-B±SE
(t, p)

28.06 ± 2
2.49 ± 2.40
(1.04, 0.30a)

41

24.44 ± 1.8
1.75 ± 2.55
(0.68, 0.49a)

85

Est. T2-T1±SE (t, p)

0.43 ± 0.21
(2.02, 0.02c)
0.21 ± 0.21
(0.99, 0.32d)
n/a
0.93 ± 0.26
(3.53, <0.01c)
0.26 ± 0.26
(0.98, 0.33d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f,
p)
(4.90, 0.03)
(1.68, 0.18)
(2.91, 0.04)
(5.77, 0.02)
(3.74, 0.01)
(4.40, <0.01)

32

n/a
2.87 ± 1.23
(2.34, 0.01c)
3.62 ± 1.22
(2.98, <0.01d)

(9.52, <0.01)

63

n/a

(0.66, 0.58)

(1.55, 0.22)

LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided

comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t:
t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction
term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. #Adjusted for baseline race and depression.

Table 4.6: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Follow-Up Assessments
Outcome

Pain Severity
Score#

Pain Interference
Score^

57
Pain
Catastrophizing
Scale*

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Follow-Up (T4)
Est µ± SE

n

5.67 ± 0.25

44

5.13 ± 0.31

25

B
Est A-B±SE
(t, p)

5.93 ± 0.25
-0.26 ± 0.36
(0.73, 0.47a)

41

25

85

6.04 ± 0.30
-0.91 ± 0.43
(2.11, 0.037a)

50

A

5.67 ± 0.19

44

4.69 ± 0.37

25

B
Est A-B±SE
(t, p)

5.59 ± 0.18
-0.08 ± 0.25
(-0.31, 0.76a)

41

25

85

5.40 ± 0.37
-0.71 ± 0.52
(1.38, 0.17a)

50

A

25.56 ± 1.64

44

21.00 ± 1.84

25

B

28.06 ± 1.71

41

23.87 ± 1.88

Est A-B±SE
(t, p)

-2.50 ± 2.40
(1.04, 0.30a)

85

-2.87 ± 2.66
(1.08, 0.28a)

Est. T4-T1±SE (t,
p)
-0.54 ± 0.28
(1.89, 0.03c)
0.11 ± 0.28
(-0.41, 0.68d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(4.90, 0.03)
(1.68, 0.18)

n/a
-0.98 ± 0.37
(2.65, <0.01c)
-0.19 ± 0.37
(0.50, 0.62d)

(2.91, 0.04)

(4.40, <0.01)

25

n/a
-4.56 ± 1.33
(3.44, <0.01c)
-4.19 ± 1.33
(3.15, <0.01d)

50

n/a

(0.66, 0.58)

(5.77, 0.02)
(3.74, 0.01)

(1.55, 0.22)
(9.52, <0.01)

LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided
comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison between Baseline
Assessment and Follow-up Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: ttest statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction
term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. #Adjusted for baseline race and depression.

Table 4.7: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Post-training Assessments
Outcome

Opioid

Non-steroidal antiinflammatory drug

58
Over-the-counter

Musculoskeletal

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-Training (T2)
Est µ± SE

n

1.33 ± 0.11

43

1.42 ± 0.14

31

B
Est A-B±SE
(t, p)

1.31 ± 0.35
0.02 ± 0.11
(0.17, 0.86a)

41

32

84

1.35 ± 0.13
0.07 ± 0.13
(0.34, 0.73b)

63

A

1.35 ± 0.10

43

1.21 ± 0.11

31

B
Est A-B±SE
(t, p)

1.32 ± 0.10
0.03 ± 0.11
(0.22, 0.83a)

41

32

84

1.51 ± 0.14
-0.3 ± 0.16
(1.77, 0.04b)

63

A

2.60 ± 0.33

43

2.43 ± 0.35

31

B
Est A-B±SE
(t, p)

2.72 ± 0.36
-0.12 ± 0.19
(0.24, 0.81a)

41
84

2.25 ± 0.33
0.18 ± 0.17
(1.35, 0.09b)

A

1.64 ± 0.15

43

1.80 ± 0.19

31

B
Est A-B±SE
(t, p)

1.47 ± 0.14
0.17 ± 0.12
(0.84, 0.40a)

41

1.29 ± 0.13
0.51 ± 0.11
(2.28, 0.01b)

84

Est. T2-T1±SE (t,
p)
0.09 ± 0.09
(0.64, 0.26c)
0.04 ± 0.11
(0.41, 0.68d)
n/a
-0.14 ± 0.10
(1.28, 0.10c)
0.19 ± 0.08
(1.51, 0.13d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(0.01, 0.92)
(1.17, 0.32)
(0.72, 0.54)
(2.43, 0.12)
(2.16, 0.09)

32

n/a
-0.17 ± 0.15
(0.48, 0.32c)
-0.47 ± 0.17
(1.35, 0.18d)

(2.27, 0.08)

(0.89, 0.45)

63

n/a

(0.88, 0.45)

(0.09, 0.77)

32

0.16 ± 0.2
(-0.66, 0.26c)
-0.18 ± 0.1
(2.42, <0.01d)

(0.07, 0.98)

63

n/a

(1.35,0.26)

(1.77, 0.19)

Table 4.7: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Post-training Assessments

Outcome

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-training (T2)
Est µ± SE

Est. T2-T1±SE (t, p)
n

1.15 ± 0.07

43

1.27 ± 0.09

31

B
Est A-B±SE
(t, p)

1.19 ± 0.07
-0.04 ± 0.09
(0.39, 0.70a)

41

32

84

1.02 ± 0.07
0.25 ± 0.10
(0.06, 0.48b)

63

A

1.44 ± 0.15

43

1.63 ± 0.19

31

B
Est A-B±SE
(t, p)

1.76 ± 0.19
-0.32 ± 0.18
(1.33, 0.18a)

41

32

84

1.94 ± 0.22
-0.31 ± 0.20
(1.09, 0.14b)

63

A

1.50 ± 0.12

43

1.48 ± 0.13

31

B
Est A-B±SE
(t, p)

1.31 ± 0.11
0.19 ± 0.002
(1.13, 0.26a)

41

1.28 ± 0.12
0.20 ± 0.11
(1.15, 0.13b)

Sleep

Anti-Anxiety

59
Anti-depressant

84

0.12 ± 0.07
(1.38, 0.08c)
-0.17 ± 0.08
(0.14, 0.89d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f,
p)
(0.03, 0.86)
(0.91, 0.44)

n/a
0.19 ± 0.08
(1.29, 0.10c)
0.18 ± 0.08
(1.06, 0.29d)

(0.07, 0.98)

(0.65, 0.59)

32

n/a
-0.02 ± 0.09
(0.10, 0.46c)
-0.03 ± 0.09
(0.28, 0.78d)

63

n/a

(1.37, 0.26)

(3.45, 0.07)
(1.32, 0.27)

(0.28, 0.60)
(0.15, 0.93)

Back-transformed logged LS-Means estimates of number of pills per day. a2-sided comparison between groups. b1-sided
test between groups. c1-sided comparison between Baseline Assessment and Post-training Assessment. d2-sided
comparison between Baseline Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1:
Timepoint 1. T2: Timepoint 2. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects
for group by timepoint interaction term (1-sided).

Table 4.8: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Follow-up Assessments
Outcome

Opioid

60

Non-steroidal antiinflammatory
drug

Over-the-counter

Musculoskeletal

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Follow-up (T4)
Est µ± SE

n

1.33 ± 0.11

43

1.30 ± 0.13

25

B
Est A-B±SE
(t, p)

1.31 ± 0.35
0.02 ± 0.11
(0.17, 0.86a)

41

25

84

1.25 ± 0.13
0.05 ± 0.15
(0.24, <0.41b)

A

1.35 ± 0.10

43

1.12 ± 0.10

25

B
Est A-B±SE
(t, p)

1.32 ± 0.10
0.03 ± 0.11
(0.22, 0.83a)

41

25

84

1.45 ± 0.12
-0.33 ± 0.2
(-1.15, 0.13b)

50

A

2.60 ± 0.33

43

2.28 ± 0.36

25

B
Est A-B±SE
(t, p)

2.72 ± 0.36
-0.12 ± 0.19
(0.24, 0.81a)

41

25

84

2.47 ± 0.39
-0.19 ± 0.24
(0.36, 0.36b)

50

A

1.64 ± 0.15

43

1.62 ± 0.18

B
Est A-B±SE
(t, p)

1.47 ± 0.14
0.17 ± 0.12
(0.84, 0.40a)

41

1.46 ± 0.16
0.16 ± 014
(0.64, 0.26b)

84

50

Est. T4-T1±SE (t,
p)
-0.03 ± 0.11
(0.28, 0.39c)
-0.06 ± 0.11
(0.41, 0.68d)
n/a
-0.23 ± 0.11
(2.16, 0.02c)
0.13 ± 0.09
(1.01, 0.31d)
n/a
-0.32 ± 0.17
(0.87, 0.19c)
-0.25 ± 0.17
(0.64, 0.53d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(0.01, 0.92)
(1.17, 0.32)
(0.72, 0.54)
(2.43, 0.12)
(2.16, 0.09)
(2.27, 0.08)
(0.09, 0.77)
(0.89, 0.45)

25

n/a
-0.02 ± 0.11
(0.12, 0.45c)

(0.88, 0.45)
(1.77, 0.19)

25

-0.01 ± 0.11
(0.02, 0.98d)

(0.07, 0.98)

50

n/a

(1.37, 0.26)

Table 4.8: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Follow-up Assessments
Outcome

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Follow-up (T4)
Est µ± SE

n

1.15 ± 0.07

43

1.17 ± 0.09

25

B
Est A-B±SE
(t, p)

1.19 ± 0.07
-0.04 ± 0.09
(0.39, 0.70a)

41

25

84

1.20 ± 0.09
-0.03 ± 011
(0.23, 0.41b)

50

A

1.44 ± 0.15

43

1.35 ± 0.16

25

B
Est A-B±SE
(t, p)

1.76 ± 0.19
-0.32 ± 0.18
(1.33, 0.18a))

41

25

84

1.84 ± 0.23
-0.49 ±0.24
(1.81, 0.07)

A

1.50 ± 0.12

43

1.33 ± 0.14

25

B
Est A-B±SE
(t, p)

1.31 ± 0.11
0.19 ± 0.002
(1.13, 0.26a)

41

1.47 ± 0.15
-0.14 ± 0.16
(0.70, 0.48b)

Sleep

Anti-anxiety

61
Anti-depressant

84

Est. T4-T1±SE (t,
p)
0.02 ± 0.08
(0.26, 0.40c)
0.01 ± 0.08
(0.14, 0.89d)
n/a
-0.09 ± 0.11
(0.65, 0.26c)
0.08 ± 0.10
(0.44, 0.66d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(0.03, 0.86)
(0.91, 0.44)
(0.07, 0.98)

(3.45, 0.07)
(1.32, 0.27)

(0.28, 0.60)

25

n/a
-0.17 ± 0.12
(1.12, 0.13c)
0.16 ± 0.10
(1.01, 0.31d)

50

n/a

(1.37, 0.26)

50

(0.65, 0.59)

(0.15, 0.93)

Back-transformed logged LS-Means estimates of number of pills per day. a2-sided comparison between groups. b1-sided
test between groups. c1-sided comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison
between Baseline Assessment and Follow-up Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4:
Timepoint 4. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by
timepoint interaction term (1-sided).

Table 4.9: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Post-Training Assessments

Outcome

PASAT+

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-Training (T2)
Est µ± SE

Est. T2-T1±SE (t, p)
n

16.9 ± 1.09

44

18.04 ± 1.19

31

B
Est A-B±SE
(t, p)

18.52 ± 1.07
-1.62 ± 1.53
(1.06, 0.29a)

41

32

85

17.37 ± 1.14
0.67 ± 1.65
(-0.4, 0.69a)

63

A

23.82 ± 0.79

44

24.99 ± 0.90

31

B
Est A-B±SE
(t, p)

23.92 ± 0.78
-0.10 ± 1.11
(0.09, 0.93a)

41

25.16 ± 0.86
-0.17 ± 1.24
(0.14, 0.89a)

(0.22, 0.64)
(11.75, <0.01)

32

n/a
1.17 ± 0.84
(-1.39, 0.09c)
1.24 ± 0.83
(-1.50, 0.14d)

(8.84, <0.01)

63

n/a

(0.12, 0.89)

HVLT+

62

85

1.14 ± 0.91
(-1.25, 0.11c)
-1.15 ± 0.90
(1.28, 0.20d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f,
p)

(1.90, 0.16)
(0.10, <0.75)

LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided
comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t:
t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction
term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for
baseline race and depression. § Adjusted for baseline race and pain.

Table 4.9: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Post-Training Assessments
Outcome

Mean Reaction
Time+

63

Lapses+

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

n

431.59 ± 17.32

44

416.32 ± 17.85

31

-15.27 ± 0.53
(-1.15, 0.13c)

(0.04, 0.84)

B

431.22 ± 16.74

41

423.37 ± 17.39

31

-7.85 ± 0.65
(-0.60, 0.55d)

(2.37, 0.11)

Est A-B±SE
(t, p)

0.37 ± 0.58
(0.01, 0.99a)

85

-7.05 ± 0.46
(-0.28, 0.78a)

62

n/a

(0.11, 0.90)

A

9.056 ± 1.164

43

8.04 ± 1.18

31

B
Est A-B±SE
(t, p)

9.054 ± 1.161
0.002 ± 0.003
(0.24, 0.81a)

41

8.004 ± 1.17
0.036 ± 0.01
(-0.02, 0.98a)

84

Est. T2-T1±SE (t, p)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)

Post-Training (T2)
Est µ± SE

31

-1.016 ± 0.016
(1.00, 0.16c)
-1.05 ± 0.009
(1.46, 0.15d)

(9.19, <0.01)

62

n/a

(0.23, 0.79)

(0.03, 0.85)

Reaction time LS-Means estimates displayed in milliseconds (ms). Back-transformed logged number of lapses displayed.
a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline Assessment
and Post-training Assessment. d2-sided comparison between Baseline Assessment and Post-training Assessment. µ:
Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: t-test statistic. f: F test statistic. p: p-value.
Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for baseline
depression. ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for baseline race and depression. §
Adjusted for baseline race and pain.

Table 4.10: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Follow-Up Assessments

Outcome

PASAT+

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-Training (T4)
Est µ± SE

Est. T4-T1±SE (t, p)
n

16.9 ± 1.09

44

20.29 ± 1.21

25

B
Est A-B±SE
(t, p)

18.52 ± 1.07
-1.62 ± 1.53
(1.06, 0.29a)

41

25

85

21.06 ± 1.14
-0.77 ± 1.68
(0.46, 0.65a)

A

23.82 ± 0.79

44

26.19 ± 0.93

25

B
Est A-B±SE
(t, p)

23.92 ± 0.78
-0.10 ± 1.11
(0.09, 0.93a)

41

26.84 ± 0.86
-0.65 ± 1.29
(0.51, 0.61a)

(0.22, 0.64)
(11.75, <0.01)

25

n/a
2.37 ± 0.88
(-2.69, <0.01c)
2.92 ± 0.88
(-3.21, <0.01d)

(8.84, <0.01)

50

n/a

(0.12, 0.89)

50

HVLT+

64

85

3.39 ± 0.94
(-3.60, <0.01c)
2.54 ± 0.94
(-2.51, 0.01d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f,
p)

(1.90, 0.16)
(0.10, <0.75)

LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided
comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison between Baseline
Assessment and Follow-up Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: ttest statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction
term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for
baseline race and depression. § Adjusted for baseline race and pain.

Table 4.10: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Follow-Up Assessments

Outcome

Mean Reaction
Time+

65

Lapses+

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

n

431.59 ± 17.32

44

407.50 ± 17.71

25

-24.09 ± 0.39
(-1.78, 0.04c)

(0.04, 0.84)

B

431.22 ± 16.74

41

413.91 ± 17.82

25

-17.31 ± 1.08
(-1.26, 0.22d)

(2.37, 0.11)

Est A-B±SE
(t, p)

0.37 ± 0.58
(0.01, 0.99a)

85

-6.41± 0.11
(-0.26, 0.80a)

50

A

9.056 ± 1.164

43

6.05 ± 1.19

25

B
Est A-B±SE
(t, p)

9.054 ± 1.161
0.002 ± 0.003
(0.24, 0.81a)

41

6.46 ± 1.18
-0.41 ± 0.01
(0.28, 0.78a)

84

Est. T4-T1±SE (t, p)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f,
p)

Post-Training (T4)
Est µ± SE

25

n/a
-3.006 ± 0.026
(2.71, <0.01c)
0.39 ± 0.16
(2.50, 0.01d)

(0.11, 0.90)

(9.19, <0.01)

50

n/a

(0.23, 0.79)

(0.03, 0.85)

Reaction time LS-Means estimates displayed in milliseconds (ms). Back-transformed logged number of lapses displayed.
a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline Assessment
and follow-up. d2-sided comparison between Baseline Assessment and Follow-up Assessment. µ: Mean. SE: Standard
error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type
3 test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for baseline depression. ^Adjusted for
baseline pain. +Adjusted for baseline race. #Adjusted for baseline race and depression. § Adjusted for baseline race and
pain.

Table 4.11: Mixed Model Analysis of Psychological Variables from Baseline vs. Post-Training Assessments
Outcome

BDI Score*

Perceived
Stress Score*

66
General
Fatigue+

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

n

Post-training (T2)
Est µ± SE

Est. T2-T1±SE (t, p)
n

A

21.9 ± 1.04

44

17.66 ± 1.22

31

B
Est A-B±SE
(t, p)

21.1 ± 1.08
0.8 ± 1.5
(-0.52, 0.6a)

41

32

85

20.97 ± 1.21
-3.31 ± 1.7
(1.92, 0.057a)

63

A

22.46 ± 0.66

44

21.72 ± 0.76

31

B
Est A-B±SE
(t, p)

23.76 ± 0.69
-1.30 ± 0.96
(1.35, 0.18a)

41

32

85

22.26 ± 0.76
-0.54 ± 1.09
(0.5, 0.62a)

63

A

12.51 ± 0.36

44

11.92 ± 0.42

31

B
Est A-B±SE
(t, p)

12.38 ± 0.36
0.13 ± 0.5
(-0.25, 0.80a)

41

12.37 ± 0.40
-0.45 ± 0.58
(0.77, 0.44a)

85

-4.24 ± 1.35
(3.14, <0.01c)
-0.13 ± 1.35
(0.1, 0.92d)
n/a
-0.74 ± 0.77
(0.96, 0.17c)
-1.50 ± 0.76
(1.96, 0.05d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(3.54, 0.06)
(5.73, <0.01)
(2.42, 0.03)
(1.66, 0.20)
(2.83, 0.04)

31

n/a
-0.59 ± 0.43
(1.36, 0.09c)
-0.01 ± 0.43
(0.04, 0.97d)

(0.38, 0.76)

(2.48, 0.06)

62

n/a

(0.45, 0.72)

(0.00, 0.97)

LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided
comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2.
t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint
interaction term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. +Adjusted for baseline race.
#Adjusted for baseline race and depression. § Adjusted for baseline race and pain.

Table 4.11: Mixed Model Analysis of Psychological Variables from Baseline vs. Post-Training Assessments

Outcome

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Post-training (T2)
Est µ± SE

Est. T2-T1±SE (t, p)
n

11.08 ± 0.32

43

11.38 ± 0.38

31

B
Est A-B±SE
(t, p)

11.68 ± 0.33
-0.60 ± 0.46
(1.3, 0.19a)

41

31

84

11.97 ± 0.38
-0.59 ± 0.54
(1.1, 0.27a)

A

13.53 ± 0.31

44

13.23 ± 0.37

31

B
Est A-B±SE
(t, p)

12.42 ± 0.31
1.11 ± 44
(-2.55, 0.01a)

41

31

85

13.39 ± 0.35
-0.16 ± 0.51
(0.31, 0.76a)

A

13.18 ± 0.37

44

13.21 ± 0.43

31

B
Est A-B±SE
(t, p)

12.42 ± 0.38
0.76 ± 0.51
(-1.48, 0.14a)

40

12.85 ± 0.41
0.36 ± 0.59
(-0.61, 0.54a)

Mental Fatigue*

Physical
Fatigue+

67
Reduced
Activity§

84

0.30 ± 0.43
(-0.71, 0.24c)
0.29 ± 0.44
(-0.67, 0.50d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint
(f, p)
(1.27, 0.26)
(0.43, 0.26)

n/a
-0.30 ± 0.42
(0.72, 0.24c)
0.97 ± 0.42
(-2.27, 0.02d)

(0.36, 0.78)

(1.83, 0.14)

31

n/a
0.03 ± 0.52
(-0.06, 0.48c)
0.43 ± 0.53
(-0.81, 0.42d)

(0.40, 0.76)

62

n/a

(0.41, 0.74)

62

62

(2.26, 0.14)
(0.89, 0.45)

(2.05, 0.16)

LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided
comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t:
t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction
term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for
baseline race and depression. § Adjusted for baseline race and pain.

Table 4.11: Mixed Model Analysis of Psychological Variables from Baseline vs. Post-Training Assessments

Outcome

Reduced
Motivation^

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A
B
Est A-B±SE
(t, p)

n

Post-Training (T2)
Est µ± SE

n

12.39 ± 0.37

44

11.97 ± 0.44

31

11.62 ± 0.39
0.77 ± 0.54
(-1.41, 0.16a)

41

11.98 ± 0.44
-0.01 ± 0.62
(0.01, 0.99a)

85

Est. T2-T1±SE (t,
p)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)

30

-0.42 ± 0.47
(0.88, 0.19c)
0.36 ± 0.48
(-0.73, 0.46d)

(0.25, 0.86)

62

n/a

(0.53, 0.66)

(0.39, 0.53)
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LS-Means estimates displayed as mean. a2-sided comparison between groups. b1-sided test between groups. c1sided comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between
Baseline Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2:
Timepoint 2. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by
timepoint interaction term (1-sided). *Adjusted for baseline depression.
^Adjusted for baseline pain. +Adjusted for
baseline race. #Adjusted for baseline race and depression. § Adjusted for baseline race and pain.

Table 4.12: Mixed Model Analysis of Psychological Variables from Baseline vs. Follow-Up Assessments

Outcome

BDI Score*

Perceived
Stress Score*

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

69

n

Follow-Up (T4)
Est µ± SE

n

21.9 ± 1.04

44

16.30 ± 1.34

25

B
Est A-B±SE
(t, p)

21.1 ± 1.08
0.8 ± 1.5
(-0.52, 0.6a)

41

25

85

20.32 ± 1.34
-4.02 ± 1.92
(2.10, 0.037a)

A

22.46 ± 0.66

44

21.66 ± 0.82

25

B
Est A-B±SE
(t, p)

23.76 ± 0.69
1.30 ± 0.96
(1.35, 0.18a)

41

25

85

23.35 ± 0.83
-1.69 ± 1.18
(1.43, 0.16a)

50

12.51 ± 0.36

44

11.86 ± 0.45

25

12.38 ± 0.36
0.13 ± 0.5
(-0.25, 0.80a)

41

11.85 ± 0.44
0.01 ± 0.63
(-0.02, 0.99a)

A
General
Fatigue+

B
Est A-B±SE
(t, p)

85

Est. T4-T1±SE (t, p)

-5.60 ± 1.46
(3.84, <0.01c)
-0.78 ± 1.47
(053, 0.59d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f,
p)
(3.54, 0.06)
(5.73, <0.01)

n/a
-0.80 ± 0.83
(0.96, 0.17c)
-0.41 ± 0.83
(0.49, 0.62d)

(2.42, 0.03)

(0.38, 0.76)

25

n/a
-0.65 ± 0.47
(1.40, 0.08c)
-0.53 ± 0.47
(1.14, 0.26d)

50

n/a

(0.45, 0.72)

50

(1.66, 0.20)
(2.83, 0.04)

(0.00, 0.97)
(2.48, 0.06)

LS-Means estimates displayed. a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison
between Baseline t and Follow-up Assessment. d2-sided comparison between Baseline and Post-training Assessment. µ:
Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 2. t: t-test statistic. f: F test statistic. p: p-value.
Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for baseline
depression. ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for baseline race and depression. §
Adjusted for baseline race and pain.

Table 4.12: Mixed Model Analysis of Psychological Variables from Baseline vs. Follow-Up Assessments
Outcome

Mental
Fatigue*

Physical
Fatigue+
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Reduced
Activity§

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A

n

Follow-Up (T4)
Est µ± SE

n

11.08 ± 0.32

43

11.53 ± 0.41

25

B
Est A-B±SE
(t, p)

11.68 ± 0.33
-0.60 ± 0.46
(1.3, 0.19a)

41

25

84

11.50 ± 0.42
0.03 ± 0.59
(-0.05, 0.96a)

0.45 ± 0.47
(-0.98, 0.17c)
-0.18 ± 0.47
(0.38, 0.71d)

50

n/a

A

13.53 ± 0.31

44

13.65 ± 0.40

25

B
Est A-B±SE
(t, p)

12.42 ± 0.31
1.11 ± 44
(-2.55, 0.01a)

41

25

85

12.80 ± 0.39
0.85 ± 0.56
(-1.51, 0.13a)

50

A

13.18 ± 0.37

44

12.81 ± 0.47

24

B
Est A-B±SE
(t, p)

12.42 ± 0.38
0.76 ± 0.51
(-1.48, 0.14a)

40

12.82 ± 0.45
-0.01 ± 0.65
(0.02, 0.98a)

84

Est. T4-T1±SE (t, p)

0.12 ± 0.45
(-0.25, 0.40c)
0.38 ± 0.46
(-0.83, 0.41d)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(1.27, 0.26)
(0.43, 0.26)
(0.36, 0.78)
(2.26, 0.14)
(0.89, 0.45)
(1.83, 0.14)

25

n/a
-0.37 ± 0.55
(0.62, 0.27c)
0.40 ± 0.55
(-0.92, 0.36d)

49

n/a

(0.41, 0.74)

(2.05, 0.16)
(0.40, 0.76)

LS-Means estimates displayed as mean. a2-sided comparison between groups. b1-sided test between groups. c1-sided
comparison between Baseline Assessment and Follow-up Assessment d2-sided comparison between Baseline
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4.
t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint
interaction term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. +Adjusted for baseline race.
#Adjusted for baseline race and depression. § Adjusted for baseline race and pain.

Table 4.12: Mixed Model Analysis of Psychological Variables from Baseline vs. Follow-Up Assessments
Outcome

Reduced
Motivation^

Group
A=Intervention
B=Control

Baseline (T1)
Est µ ± SE

A
B
Est A-B±SE
(t, p)

n

Follow-Up (T4)
Est µ± SE

n

12.39 ± 0.37

44

12.39 ± 0.48

25

11.62 ± 0.39
0.77 ± 0.54
(-1.41, 0.16a)

41

12.14 ± 0.49
0.25 ± 0.69
(-0.37, 0.71a)

24

-0.002 ± 0.51
(-0.00, 0.50c)
0.52 ± 052
(-0.98, 0.32d)

49

n/a

85

Est. T4-T1±SE (t, p)

Group (f, p)
Timepoint (f, p)
Group x Timepoint (f, p)
(0.39, 0.53)
(0.25, 0.86)
(0.53, 0.66)
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LS-Means estimates displayed as mean. a2-sided comparison between groups. b1-sided test between groups. c1-sided
comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison between Baseline
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t:
t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction
term (1-sided). *Adjusted for baseline depression.
^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted
for baseline race and depression. § Adjusted for baseline race and pain.

Table 4.13 Cohen’s D Estimates for Outcomes
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Outcome

TP2-TP1

Pooled SD

Cohen’s D1

TP4-TP1

Pooled SD

Cohen’s D2

HRV Coherence
Pain Severity
Pain Interference
Pain Catastrophizing
Paced Auditory Serial Addition Test

0.4464
-0.2319
-4.6472
0.5252
2.00

0.6392
1.0277
8.7967
6.8512
5.26

0.70
-0.23
-0.53
0.07
0.38

0.4529
-0.9600
-5.9922
-1.4800
0.4800

0.5456
1.4549
16.0202
7.5542
4.5249

0.83
-0.66
-0.37
-0.20
0.11

Hopkins Verbal Learning Test

0.1613

4.8529

0.03

-0.8000

5.2144

-0.15

Beck Depression Inventory
Perceived Stress

-4.6472
0.5927

8.7967
4.9926

-0.53
0.12

-5.3600
-0.3600

8.9607
3.8794

-0.60
-0.09

General Fatigue
Mental Fatigue
Physical Fatigue
Reduced Activity
Reduced Motivation

0.2333
0.2667
-0.0667
0.1000
0.3381

3.2749
2.8426
2.7224
3.5025
2.7766

0.07
0.09
-0.02
0.03
0.12

0.2833
0.1633
.0383
-0.3982
0.2120

3.3129
3.1477
2.7707
3.2132
3.6650

0.09
0.05
0.01
-0.12
0.06

TP2-TP1: Difference score of group means between post-training and baseline, Pooled SD: Pooled Standard Deviation,
Cohen’s D1: Cohen’s D Estimate between post-training and baseline, TP4-TP1: Difference score of group means between
follow-up and baseline, Cohen’s D2: Cohen’s D Estimate between follow-up and baseline.

Table 4.14. Demographics by Completion Status
Total (n=76)

Completers (n=50)

Loss to Follow-up (n=26)

By Group
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Intervention
Control
Age (years± SD)
Gender
n (%)
Female (%)
Male (%)
Race
Minorities (%)
Caucasian (%)
Education
Less Than College
College
Graduate School
Income
Under $30,000
$30,000-50,000
$50,001 or more
Refused
Don’t know

p-value
1.00

38 (50)
38 (50)
55 ± 11

25 (66)
25 (66)
57 ± 9.9

13 (34)
13 (34)
50 ± 11.6

26 (35)
49 (65)

19 (38)
30 (60)

7 (27)
19 (73)

47 (62)
29 (38)

32 (64)
18 (36)

15 (58)
11 (42)

0.01
0.63

0.62

0.14
20 (26)
47 (62)
9 (12)

15 (30)
27 (54)
8 (16)

5 (19)
20 (77)
1 (4)
0.31

31 (41)
15 (20)
25 (33)
4 (5)
1 (1)

18 (36)
12 (24)
15 (30)
4 (8)
1 (2)

13 (50)
3 (12)
10 (38)
0 (0)
0 (0)

Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for categorical variables. Pooled T-test used for
continuous variables. n: number SD: Standard Deviation.

Table 4.15. Comorbidities at Baseline by Completion Status
Overall (n=76)

Completers (n=50)

Loss to Follow-up (n=26)

Yes (%)
No (%)

34 (45)
42 (55)

24 (48)
26 (52)

10 (38)
16 (62)

Yes (%)
No (%)

8 (11)
68 (89)

6 (12)
44 (88)

2 (8)
24 (92)

Hypertension
Cancer

p-value
0.47
0.71

Depression

0.34
Yes (%)
No (%)

35 (46)
41 (54)

21 (42)
29 (58)

14 (54)
12 (46)

Yes (%)
No (%)

17 (22)
59 (78)

12 (24)
38 (76)

5 (19)
21 (81)

Anxiety

0.78
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PTSD

0.08
Yes (%)
No (%)

28 (37)
48 (63)

22 (44)
28 (56)

6 (23)
20 (77)

Yes (%)
No (%)

19 (25)
57 (75)

12 (24)
38 (76)

7 (27)
19 (73)

Diabetes

0.78

Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for categorical variables. Pooled T-test used for
continuous variables. n: number SD: Standard Deviation. PTSD: Post Traumatic Stress Disorder.
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Figure 4.1. Back-transformed log HRV Coherence LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05
vs Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post
value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and
assessment indicated at base of each bar.
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Figure 4.2. Back-transformed log LF Power LS Means ± SE msec2/Hz by treatment group and assessment. a1-sided, p
< 0.05 vs Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05
vs Post value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and
assessment indicated at base of each bar.
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Figure 4.3. Pain Severity Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value
in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same
group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at
base of each bar. Adjusted for race and depression at baseline.
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Figure 4.4. LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value in the same group.
b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same group. d1-sided, p
< 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at base of each bar.
Adjusted for pain at baseline.
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Figure 4.5. Pain Catastrophizing Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs
Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post
value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and
assessment indicated at base of each bar. Adjusted for depression at baseline.
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Figure 4.6. Back-Transformed non-steroidal anti-inflammatory drug use LS Means ± SE by treatment group and
assessment. a1-sided, p < 0.05 vs Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same
group. c1-sided, p < 0.05 vs Post value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of
patients within each group and assessment indicated at base of each bar.
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Figure 4.7. Back-Transformed Opioid LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline
value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the
same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment
indicated at base of each bar.
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Figure 4.8. Paced Auditory Serial Addition Test LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05
vs Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post
value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and
assessment indicated at base of each bar. Adjusted for race at baseline.
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Figure 4.9. Hopkins Verbal Learning Test LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs
Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post
value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and
assessment indicated at base of each bar. Adjusted for race at baseline.
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Figure 4.10. Back-transformed Reciprocal Mean Reaction Time LS Means ± SE by treatment group and assessment. a1sided, p < 0.05 vs Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p
< 0.05 vs Post value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each
group and assessment indicated at base of each bar. Adjusted for race at baseline.
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Figure 4.11. Lapses LS Means ± SE log transformed then back-transformed by treatment group and assessment. a1sided, p < 0.05 vs Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p
< 0.05 vs Post value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each
group and assessment indicated at base of each bar. Adjusted for Race at baseline.
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Figure 4.12. Beck Depression Inventory LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs
Baseline value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post
value in the same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and
assessment indicated at base of each bar. Adjusted for depression at baseline.
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Figure 4.13. Perceived Stress Scale LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline
value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the
same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated
at base of each bar. Adjusted for depression at baseline.
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Figure 4.14. General Fatigue Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline
value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the
same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated
at base of each bar. Adjusted for race at baseline.
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Figure 4.15. Mental Fatigue Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline
value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the
same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment
indicated at base of each bar. Adjusted for depression at baseline.
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Figure 4.16. Physical Fatigue Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline
value in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the
same group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated
at base of each bar. Adjusted for race at baseline.
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Figure 4.17. Reduced Activity LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value
in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same
group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at
base of each bar. Adjusted for race and pain at baseline.
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Figure 4.18 Reduced Motivation LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value
in the same group. b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same
group. d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at
base of each bar. Adjusted for pain at baseline.

CHAPTER 5
DISCUSSION
5.1 Overall Discussion
Results from this study indicate the receipt of HRVB can improve HRV
coherence in veterans with chronic pain. HRV Coherence has been shown to help
reduce clinical symptoms in other studies.8 For example, in a population of human
immunodeficiency viral disease (HIV) patients, HRVB helped to reduce anxiety. 210
HRVB helped improve emotional well-being and lower blood pressure in those with
high blood pressure.211 Among physicians, HRVB helped reduce stress.212 In a
group of congestive heart failure elderly patients, HRVB improved symptoms of
depression.213

In the current study, receipt of the HRVB intervention was

demonstrated by a statistically significant improvement in the HRV Coherence
Ratio values. Large effect estimates of the HRV Coherence Ratio were noted when
comparing baseline to post-training values (d=0.7) and baseline to follow-up
(d=0.83) in the intervention group (Table 4.13). This is evidence that the
biofeedback technique was received and sustained over the course of the study.
Both groups had a statistically significant improvement in Low Frequency
Power. Improvement in LF for those in the control group may have been due to
some sham-induced relaxation that also facilitated resonant frequency breathing
in that group. This may be a result of sitting in a relatively quiet, calm, supportive
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atmosphere while watching peaceful, static images of nature scenes. Improvement
in LF power suggests an improvement in parasympathetic stimuli.214 Van der Zwan
et al. conducted a study to evaluate efficacy of physical activity, mindfulness
meditation, and HRVB with twenty adult volunteers aged 18-40 years old in
Amsterdam who reported stress with a PSS cut-off score of 17. Participants were
stratified by gender and age then randomized into one of three groups. After a
Baseline Assessment, five weekly training visits were conducted over 2-hours and
a stair-stepped approach of intervention at home from 10-20 minutes over the five
weeks. This was followed by a Follow-up Assessment. Van der Zwan et al. found
no statistical differences between the three, and found all equally improved stress,
anxiety, depression, and a general sense of well-being.25 Possibly, sitting
passively observing nature scenes may mimic mindful meditation in which if that is
the case, it would explain why the control group in the current study also improved
their LF power. An increase in HRV coherence in the current study suggests the
intervention group received and benefited from HRVB and that the intervention
was sustained over four months. A strength of Van der Zwan’s study is the
comparison of physical activity, HRVB, and meditation, however two limitations are
the very small number of participants enrolled (n=20) and another is the short
duration of the study. It would be interesting to see if there were any differences
in the groups over a longer period with additional assessments longitudinally and
to see if one group sustained benefit longer than others. A benefit of the current
study is the larger sample size (n=85) between two groups and was evaluated over
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four months which demonstrated sustainability and improved duration of the HRVB
intervention.
5.2 Pain Discussion
The current study demonstrated a reduction in pain severity in the
intervention group relative to the control group. A small effect estimate was noted
between baseline and post-training (-0.23, Table 4.13) whereas a medium effect
was noted between baseline and follow-up (d= -0.66, Table 4.13). This suggests
that the use of HRVB has the potential to reduce pain severity in those who
experience chronic pain. Further, pain interference was also statistically
significantly reduced in those who received HRVB. A medium effect size was noted
from baseline to post-training (-0.53, Table 4.13) and later a small effect size from
baseline to follow-up (-0.37, Table 4.13) suggesting pain that interferes with daily
activities may be reduced in those who practice HRVB. This reduction in both
outcomes can be attributed as a result of the benefit of HRVB. Both groups had a
statistically significant reduction in pain catastrophizing scores from baseline to
follow-up. When comparing group differences at follow-up, there was no
statistically significant difference between the intervention group and the control
group (p=0.28, Table 4.13). Small effect sizes for pain catastrophizing were also
noted from baseline to post-training (0.07, Table 4.13) and baseline to follow-up (0.20, Table 4.13) in the intervention group (Table 4.13). The reduction may not
have been completely due to HRVB, another possible factor to consider is the
potential for a placebo effect. In a double-blinded, randomized control trial by
Kapitza et al., 42 participants between the ages 18-70 years, with chronic low back
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pain were enrolled into either an HRVB intervention or a placebo group. The
participants were fitted for a machine to use at home in which the HRVB group had
tailored resonance frequency breathing with feedback whereas the control group
had no feedback and the device was set to about eight breaths per minute.
Participants provided baseline data, 30 minutes of training at home for 15 days,
follow-up at two weeks and at 3 months post intervention. A reduction in pain of
approximately 25% was reported in the intervention group as compared to the
control group. In the study by Kapitza, there were no dropouts, however in the
current study, a loss-to-follow-up of about 33% was observed.21
In a separate study by Berry et. al., the use of HRV coherence biofeedback
was randomly assigned in a pilot study of 14 U.S. military veterans with chronic
pain allocating them to an HRVB intervention group and a placebo group.
Following the Baseline Assessment, four weekly HRVB training visits were
conducted prior to a Post-intervention Assessment. A greater reduction of pain
was observed in the HRVB group as compared to the control group at postintervention (p=0.04) and a reduction in pain from pre- to post-intervention was
reported in the HRVB group (p=<0.001).4 A limitation of the study is the small
number of participants (n=14), along with the limited number of test outcome which
used the BPI and PSS. However, similarities exist with the current study in that
both populations were U.S. military veterans with chronic pain. Berry et al used
four weeks of HRVB, whereas the current study prescribed six weeks Improved
HRV coherence and reductions in pain were observed in the HRVB groups.
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In the present study, reductions in medication used were found only for nonsteroidal anti-inflammatory drug use in the intervention group and a slight but
statistically significant reduction in opioid use in the intervention group between
Post-training and Booster Assessment. This reduction in opioid use occurred after
an unexplained increase in opioid use post-training and most likely is an artifact.
The current study included all opioids in one category. Future studies should
consider quantification of morphine equivalents and comparing quantity consumed
before and after HRVB intervention. While a sustained reduction in opioid use was
not achieved during the current study, the use of a longer study, possibly with a
larger sample size could further elucidate if HRVB leads to reductions in pain and
in opioid use. As chronic opioid use has potential for side-effects, so does
separation from opioid use. In opioid addiction, on average, it takes a minimum of
90 days of rehabilitation and a minimum of 12 months for methadone treatment to
see limited benefit.94 Reductions in NSAID use may indicate that HRVB benefitted
pain management among participants in a relatively short period of time. The
results of the current study are consistent with other studies, which have also
demonstrated a reduction of pain through the use of HRVB.4, 21-23, 39, 75 Hassett and
associates assessed HRVB in a small sample (n=12) of female patients with
fibromyalgia aged 18-60 years old from a rheumatology clinic utilizing ten weekly
training sessions over three months with a pre- and post-assessment.22
Participants were asked to practice for two 20-minute sessions per day and asked
to refrain from caffeine or alcohol for 12 hours prior to assessments. Reductions in
pain and depression were noted.22 Hallman and colleagues included 24
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participants (22 female, 2 male) aged 25-50 years old with chronic shoulder and
neck pain along with perceived stress, randomly assigned to intervention or
control.

Reductions in pain were found with pre- and post-intervention

measurements, 10 weekly training sessions, and practice at home 15 minutes per
day for 5 days per week.39 Similarities exist with Hallman’s study and the current
study. Both were single-blind with an intervention and a control group. Both utilized
personnel trained and credentialled in HRVB.
Multiple studies have used varying lengths of training with an HRVB trainer
from 4-10 weeks and home practice of 15 to 20 minutes per day or twice a day.
Improvements in HRV have been reported through receipt of HRVB however a
standardized length of training and a standardized amount of home training have
not been yet established. Future studies should consider what is the minimum
number of training sessions required to reach HRVB coherence and what is the
minimum amount of home practice required to maintain that skill.
5.3 Cognitive Discussion
The PFC has been described as having an association with HRV and
inhibitory control.215-217 High levels of HRV while resting have been associated with
positive performance in executive function, cognitive flexibility, and in control of
inhibition218, however as noted by Gillie and Thayer, individual differences may be
linked to cognitive performance.215 HRVB has demonstrated improvement in
cognitive performance in previous studies.4, 7, 8, 12
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PASAT has been used in numerous studies to assess cognitive processing,
speed of information processing, measures of sustained attention, concentration,
and working or immediate memory. This multifactorial test requires both
information processing speed and task completion.219 Both groups had statistically
significant improvements in PASAT at follow-up. When evaluating effect estimates
for PASAT, initially a small to medium effect was noted (d= 0.38, Table 4.13) from
baseline to post-training, whereas a smaller effect was found from baseline to
follow-up (d= 0.11, Table 4.13). The increases in both groups over time may have
been due to a learning effect.
In a comprehensive review of the PASAT, numerous published comments
appear to explain many of the findings in the current study. For example, the
PASAT is an auditory test or can be performed visually as a paced visual serial
addition test (PVSAT). In the current study, it was an auditory test. The most
common reported results are the correct number of responses for each trial when
multiple trials are given or as with this study the sum of the correct number of
responses overall. Others have suggested reporting the number of omissions and
errors.219 Tombaugh suggests that most errors by the participant are the result of
not answering as opposed to delayed answering. Some have noted that the
participant may willingly skip a number to get the next one. This has been called
“chunking” and is considered less taxing to the individual and could hinder
identifying cognitive impairment. This may be where two numbers are summed,
then they skip one or two numbers, and then resume. To overcome this, patterns
could be identified and measured in “dyads” of consecutively provided correct
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answers.219 A study examined the total number of correctly answered pairs of
numbers. In some instances, participants keep track of numbers with their fingers,
and differences may be present due to how the task is calculated rather than how
quickly information is processed.219 In the current study, data was not collected if
people were using their fingers to keep track of the last stated number. This author
did however witness some participants whispering numbers to themselves to keep
track of the last heard number.
It has been suggested that due to the inherent stressful nature of the
PASAT, frustration and anxiety are common even among cognitively intact
individuals. With repeated exposure, a desensitization may occur, decreasing the
novelty, and allowing for improved performance. Increased comfort in performing
the exam may occur when anxiety reduces with repeated exposure, allowing for
increased concentration which may be a possibility for the findings in the current
study. Numerous authors have noted it to be unnecessarily stressful and some
have even noted participants would rather have a lumbar puncture than go through
the trials and tribulations of performing the PASAT.219 To reduce negative arousal,
the participant should be notified in advance that the PASAT is a stressful test and
that it should be administered at the end of a neurocognitive test battery. Even
though this is not a pass or fail test, some people will feel as though they failed. 219
Anecdotally, many subjects commented to this researcher of the difficulty of the
PASAT and some expressed concern of having to perform it on their 2nd, 3rd, or 4th
assessment having recalled their baseline experience.
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In a convenient sample of undergraduate psychology students, 95
participants were randomly assigned to a resonance frequency group (RF), a
resonance frequency +1 additional breath/minute pace (RF+1), and a control
group that sat quietly while conducting the PASAT. In that experiment, PASAT was
used as a stressor while mood, HRV values, and blood pressure were assessed
as outcomes. Systolic blood pressure remained lower and mood was more positive
in the resonance frequency group relative to the controls while the resonance
frequency group was not statistically different relative to the RF+1 group as the
PASAT was conducted.220
When considering the results for the HVLT in the current study, both groups
demonstrated improvement over time. If improvement had only been seen in the
intervention group, then it may have resulted from the HRVB training. Since both
groups improved, the results cannot be fully attributed to HRVB. Small effect sizes
were observed from baseline to post-training (d=0.03) and from baseline to followup (d= -0.15, Table 4.13). A possible limitation of this study was that it did not
measure delayed recall in which the participant would try to recall as many words
as possible after a set number of minutes or after other tasks.

It would be

interesting to assess delayed recall in addition to immediate recall in future studies.
Several studies have suggested that executive function is a direct reflection
of HRV, and as executive demands increase, participants should exhibit lower
HRV.158 However, other studies have not shown a direct correlation with increased
executive demand and lower HRV.158

Luque-Casado et al. proposed that

workload, or perceived difficulty of a task, along with the amount of time spent on
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the task was more of an indicator for low HRV than the actual task itself. The
National Aeronautics and Space Administration (NASA) developed a tool that was
sensitive to mental workload. Using the NASA Task Load Index (NASA-TLX),
Luque-Casado and colleagues evaluated subjective data of perceived mental
stress through workload with objective HRV data. Twenty-four undergraduate
Spanish males age 18-28 were enrolled, conducted the PVT (vigilance), N-back
test (measured working memory to respond to a stimulus if it matched a stimulus
two trials before), a duration discrimination task (respond if a stimulus duration was
longer or shorter compared to another), and an oddball condition (indicated if an
infrequent characteristic displayed during a frequent characteristic), all while
recording HRV measures. The oddball task was used as a control measure.
Results displayed sensitivity of HRV to sustained attention. The researchers noted
that HRV varied with the demands of the tasks and that lower HRV values were
observed with the N-back test. It was noted that when they compared the oddball
tests with the other three, the oddball and the N-back tests had twice the number
of trials (in 12 minutes) as the PVT and the discrimination test. As there were more
trials over a longer time, sustained attention in the N-back provided increased
workload, thus influenced HRV more so than cognitive control, perceptual
processing, working memory, or the individual tasks themselves.158 This
corresponds with research conducted by Hansen, Johnsen, and Thayer which
suggested that those who had high levels of HRV, performed better with increased
workload as compared to those with low levels of HRV124 and corresponds with
research by Fairclough and Houston which noted that HRV reduced with longer
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time-on-tasks.221 In the current study, HRV measurements were recorded prior to
recording PASAT and HVLT measurements. As a result, the current study is not
able to determine how HRV fluctuated during the PASAT and HVLT. Furthermore,
as both the PASAT and HVLT are tests that require speaking, it would be nearly
impossible to maintain a resonance frequency breathing rate while conducting
those

tests.

Future

studies

should

consider

including

recording

HRV

measurements while conducting cognitive tests which would allow for an initial
resting assessment, an assessment with an increased workload during the
cognitive tests, and then follow-up with a same-day post-assessment resting
recording to allow for comparisons at rest, with increased workload and time-ontask, and then a period of recovery.
Although there were no differences in PASAT and HVLT outcomes between
treatment groups, some of the participants did acknowledge they had a difficult
time hearing the recording. Use of different speakers for the computer (both
internal and external) provided the same difficulty for some participants. For
continuity and consistency, the same recordings of words were used throughout
this study. For future consideration, quality of recordings must be ensured, and
alternate speaker systems may be used. This study did not inquire if the participant
required hearing aids nor did it ensure they were wearing prescribed hearing aids
at each of their visits for this study. A strength of this study is that both groups had
the same list of words for the same assessment visits and a different list of words
were used at each of the three assessments. Lists of words were nouns that are
common in daily life and are tangible such as corn, hammer, dentist, etc. These
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are words that could be mentally visualized.

Many of the veterans told this

researcher they noticed a pattern of three groups which helped them to improve
on the second and third trial at each of the assessment visits. The most likely
reason for improvements observed in both the intervention and control group in
both the PASAT and HVLT is a practice effect.
Reaction time improved in the intervention group but not in the control
group. Reaction time is an aspect of cognitive processing of vigilant attention.
Improvement in HRV using HRVB has the potential to synchronize neurocardiovascular coupling, improve blood flow, and restore cognitive processes,
thereby facilitating faster reaction time in those who utilize HRVB. In the current
study, the PVT was conducted over a period of 10 minutes. This sustained
attention with an increased workload of varying time intervals between stimuli
further illustrates the importance of HRVB in cognitive ability to maintain vigilance
to respond more quickly in the intervention group compared to the control group.
Impaired error processing is caused by decreased attention and reduced attention
from mental fatigue.222 When sustained attention is given to a task, mental fatigue
may ensue, resulting in slower cognitive processing and increased errors. When
a person recognizes they made an error, reaction time slows.222 This has further
implications for athletes, military and law enforcement members scanning for
threats, and those in high risk occupations, such as airline pilots, where quick
reaction to potential concerns is needed. This study did not conduct resonance
frequency breathing during PVT testing, however resonance frequency breathing
in the HRVB group was conducted immediately prior to conducting the cognitive
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tests. Only a couple of minutes would have lapsed between HRV measurements
and moving four feet away to the computer for cognitive tests. It would be
interesting to explore reaction time while performing resonance frequency
breathing in future studies. A hypothesis would be that performing resonance
frequency breathing during PVT testing would facilitate faster reaction times.
As it pertains to the number of lapses, both groups demonstrated reduced
lapses over time. This may be explained by a learning effect or an intention to want
to perform better. Furthermore, at the time of the final assessment (Follow-up),
participants were exposed to two previous opportunities to gain experience and
understand how the test is conducted. Former military members are likely to be
competitive and want to personally demonstrate self-improvement either for selffulfillment or to gain approval and positive affirmation from testers. This may
explain why both groups demonstrated improvement over time. As noted by
Prinsloo et al, often times participants sacrifice speed for accuracy or conversely
sacrifice accuracy for speed.123 It is possible those in the control group
demonstrated a reduction in lapses by sacrificing speed for accuracy. However,
the number of lapses has been suggested to be directly influenced by fatigue and
sleep deprivation.223 Therefore, it is conceivable that those who continued to be
sleep deprived or fatigued may have been more likely to miss the visual stimuli,
thus causing a lapse(s).
Psychomotor tasks and behavior are affected by time-on-task as well158 as
is seen following sleep deprivation. 198 The vigilance and reaction time components
of psychomotor vigilance tasks such as learning new skills and short-term memory
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as well as fatigue and mental concentration are negatively affected by poor sleep,
leading to increased time-on-task and increased lapses.198 The PVT is a high
workload test demanding vigilant attention.198 Symptoms of sleep deprivation may
be expressed as difficulty concentrating thus facilitating lapses and slower reaction
times, changes in mood (stress and fatigue) and reduced motivation.198 LF power
has been highly correlated with PVT lapses.224 In those who were sleep restricted,
a correlation was found between HRV in the 0.01–0.08 Hz band and PVT
lapses.225 However, the current study found no correlation between PVT lapses
and LF power in the 0.04-0.15 Hz range, however both the intervention and the
control group had decreases in the number of lapses.
The 10-minute version of the PVT was used in the present study. A longer
version of the PVT leads to more lapses and longer reaction time due to waning
attention and monotony.226 Lim et al198. note that when sleep is deprived, or
subjects have prolonged wakefulness, reaction time is slower, more errors of
commission are made, and is difficult for participants to stay focused on the
task.198,

223, 226

Time-on-task has been previously reported to be inversely

proportional to HRV measurements. While the focus of this analysis does not
pertain to sleep measurements, future studies should consider how HRVB
influences sleep quality and quantity in conjunction with cognitive performance.
A quasi-experimental descriptive study was conducted among 26 male
PTSD Vietnam war veterans and 21 male normal Vietnam war veterans.227
Outcomes included learning and memory utilizing an auditory-verbal learning as
well as a visuospatial information test, in addition to an intelligence quotient (IQ)
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test and arithmetic test. Those with PTSD recalled fewer words, demonstrated
lower IQ than non-PTSD veterans and in those on psychoactive medications
performed more poorly on the arithmetic testing than those not medicated. This
study concluded that higher education may buffer development of PTSD.227 In a
separate study, Vasterling examined 961 Soldiers preparing for the war in Iraq.
Those who deployed demonstrated compromised attention and visuo-spatial
memory and increased tension and confusion.127 It is unclear how many people in
the current study deployed as deployment history was not gathered. Deployment
history should be considered in future studies. While individual differences and
experiences may be interesting to compare and could possibly confound a study,
randomization in the current demonstrated effectiveness as there were no
differences in PTST, anxiety, and other disorders between the HRVB and control
groups.
HRVB was used in a study of PTSD veterans including ten combat
veterans; five with PTSD (intervention) and five without PTSD (controls). Patients
in the intervention group were provided with four weeks of HRVB training. Attention
and immediate memory were both statistically and clinically significant, with an
increase in learned words in the HRVB group and a small decrease in words
learned in the control group.8
In summary, the PASAT, a measure of speed, attention, and the working
memory component of executive function, demonstrated both groups improved.
The HVLT, a measure of executive function, verbal and working memory, and to a
lesser degree, attention, demonstrated both groups improved.
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The PVT, a

measure of sustained vigilance, demonstrated an improvement in the HRVB
intervention group. As both HVLT and PASAT have the potential for a learning
effect, this may explain why an improvement was seen in both groups. An
improvement was noted in the HRVB intervention group but not in the control group
for the PVT which demonstrates the receipt of HRVB lead to an improvement in
reaction time. Furthermore, stress loads in PASAT and HVLT may be higher than
in PVT and attenuated benefits from the HRVB intervention. Future studies should
evaluate in finer detail the cognitive functions and stress load of each of these tests
while recording HRV measurements in a resting state, during task performance,
and then followed by a resting state after testing to evaluate how much HRV
changes from rest to stress and then how quickly, if at all, HRV returns to pretesting
levels. As time-on-task is a crucial matter for cognitive function tests, the PASAT
and HVLT were conducted over the course of about 4 minutes each, whereas the
PVT was conducted over 10 minutes. If longer versions of the PASAT and HVLT
were conducted over 10 minutes for example, it would be hypothesized that those
in the HRVB intervention group would demonstrate a significant improvement over
and above those in the control group. Lastly, it would be hypothesized those in the
HRVB intervention group who conduct resonant frequency breathing during the
PVT would demonstrate less reduction in HRV during testing, would demonstrate
decreased reaction time, and would result in a fewer number of lapses of the PVT
as compared to the control group.
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5.4 Depression, Stress, and Fatigue Discussion
In the present study, HRVB training improved depression symptoms
immediately following the training and was evident two months later at the Followup Assessment. Medium effect sizes were observed from baseline to post-training
(-0.53, Table 4.13) and from baseline to follow-up (-0.60, Table 4.13). This finding
is consistent with previous studies, all of which that had fewer participants.
Improvement in depression was reported by Windthorst and colleagues in a study
among 28 women with chronic fatigue and refractory depression who were
randomized into an HRVB or a graded exercise training group. HRVB was
provided for 10 training sessions and a reduction in both depressive symptoms
and fatigue was reported over a five-month period.44 Another study reported
improvements in major depressive disorder (MDD) in eight participants over a 10
week period.40 To the author’s knowledge, the current study is the largest
randomized controlled study of US military veterans to show a statistically
significant improvement in depression due to HRVB.
There is a growing acceptance in the Western world for the benefits that
can be derived from alternative stress-reducing therapies.25, 228 Van der Zwan and
colleagues conducted a randomized HRVB trial among 76 individuals 18-40-years
old. Outcomes included measures of depression, anxiety, and stress. The
interventions entailed 20 minutes of daily exercise, meditation, or HRVB for five
weeks. The largest effects were found with physical activity/exercise. Depression
did not improve in the HRVB group. There were no statistically significant group
differences for any of the outcomes. Small but statistically significant
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improvements in psychological well-being were observed among the HRVB group.
However, on average, those in the physical activity group exercised longer than
the other groups spent in their intervention (meditation, HRVB), therefore protocol
compliance differed.25 In the current study, protocol compliance was the same
between groups and depression was improved in the intervention group indicating
HRVB was successful at reducing depression in the intervention group.
In a study of 32 female college students (ages 18-25 years) with MDD,
HRVB was compared with treatment as usual (TAU), or a non-depressed control
group. 41 MDD can be defined as a unipolar depressive disorder displaying five of
nine symptoms most days over the course of two weeks: (depressed mood, loss
of

interest/pleasure,

weight

or

appetite

change,

insomnia/hypersomnia,

psychomotor retardation or agitation, loss of energy or fatigue, impaired
concentration or indecisiveness, worthlessness or guilt, thoughts of death or
suicidal ideation/attempt).229-231 Randomization for those with depression occurred
into the HRVB+TAU or the TAU group. Five weekly HRVB training sessions were
administered, and participants were encouraged to practice 15-20 minutes per day
4-5 times per week. HRV measurements did not improve in the TAU (medication)
group alone relative to HRVB+TAU. However, greater increases in HRV were
found with HRVB+TAU (psychotherapy) and greater decreases in BDI scores
among those with MDD compared to those without MDD.41
Karavidas conducted an open-label research study in which all 11
participants with MDD age 25-58 received HRVB training with 10 weekly sessions
and encouraged to practice twice daily for 20 minutes each. A decrease in
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depression severity and total BDI scores was noted in the group. A very large effect
size (d=3.6) was noted in the Hamilton Depression Scale with a reduction in
depression and statistically significant reduction in BDI from baseline to sessions
4, 7, and 10.40 Consistent with the present study, BDI was reduced through the
use of HRVB. A limitation of the study by Karavidas is the small number of
participants. In comparison to the current study, nearly eight times as many
participants were enrolled as with Karavidas’ study. A strength of the above study
is the encouragement to practice HRV twice a day for 20 minutes as compared to
15 minutes in the current study and ten training visits were conducted compared
to six in the current study. It would be interesting to see if effect sizes were even
more improved in the current study by either increasing the number of sessions or
to increase the frequency and duration of home training visits.
Zucker et al. conducted HRVB in a randomized pilot study of 38 people
diagnosed with PTSD (ages 18-60), comparing HRVB and progressive muscle
relaxation with a 4-week post-intervention follow-up and practicing 20-minutes per
day averaging 5-6 practices per week. These participants were in a residential
facility for substance abuse. A group by time interaction was found for
improvements in SDNN. While no group by time interaction was found for PTSD
symptom tests, reductions were found in PTSD symptoms in both groups from preto post-intervention. A reduction in BDI was found when it was used categorically;
over 94% of the intervention group reduced in severity one category (mild
depression=0-13, moderate= 14-19, and sever 29-63).36 Consistent with the
current study, a decrease in depression was noted, however in the current study

111

an increase in SDNN was not found in the HRVB group. While Zucker et al did find
a reduction in PTSD symptoms, the current study did not observe a statistically
significant reduction in stress in the intervention group. As it pertains to practice
time, the current study recommended 15 minutes per day each day. It also is
noteworthy that those with current substance abuse were excluded from the
current study. Upon completion of any substance abuse rehabilitation program,
potential participants had to remain sober for at least six months prior to being able
to enroll. Substance abuse and withdrawal have direct implications on HRV
measurements.232-234
No statistical differences in perceived stress were noted between groups in
the current study, and small effect sizes were observed between baseline to posttraining as well as baseline to follow-up respectively (d= 0.12 and -0.09, Table
4.13). There are several published studies pertaining to stress and HRVB among
veterans focusing on PTSD patients that reported improvements in stress.36, 235-237
Of the 85 participants who enrolled in this study, 38 were diagnosed with PTSD at
baseline and they were equally distributed between the two groups. Perceived
stress may be due to situations in the lives of the participants that are either chronic
or may have occurred just prior to conducting the assessments. For example, a
participant may have received the intervention and demonstrated improvement in
HRV coherence, however due to both chronic and acute situational stressors, the
participant may not have felt that their stress level had improved. Anecdotally,
there was one specific participant in the intervention group that did just this. Her
HRV coherence significantly improved, however chronically, she was providing
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care for her elderly mother while acutely, a 2-year-old niece she had previously
provided care for died of congenital birth defects during this study. Consideration
should be given to evaluate the composition of perceived stress in future studies.
In a study by Ratanasiripong and researchers, HRVB was conducted with
60 second-year baccalaureate nursing students in Thailand comparing a control
group with an intervention group over five weeks. As they entered their clinical
training, those who received HRVB demonstrated essentially no change in stress
level, although a reduction in anxiety was observed relative to the control group.238
Similar to perceived stress, no statistically significant improvements were
noted in general fatigue or the fatigue subscales in the present study, and small
effect sizes were also noted among the fatigue assessments (Table 4.13). Smets
and coauthors describe fatigue as a normal feeling resulting from physical exertion
such as with exercise or due to insufficient sleep. While fatigue may be a symptom,
Smets suggests that it could be a precursor to other disease outcomes and could
also be analyzed as an outcome for treatments.172 The benefit of a
multidimensional inventory to measure fatigue as compared to a single dimension,
is that one person could feel mentally alert while being physically tired or a person
could feel mentally tired but express physical stamina.172 Analyses of the five
components of the MFI showed improvement in all five fatigue categories (general,
mental, physical, activity, and motivation) after HRVB.44 As the follow-up was
observed at five months post-intervention, it may be that fatigue takes a longer
period of time to recover. In the current study, fatigue was measured up to four
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months after Baseline Assessment. Future studies should consider at least five
months of follow-up to ascertain if fatigue takes longer to recover.
5.5 Strengths and Limitations
As this is a randomized control trial, one study strength of this design is
reduced confounding and selection bias. Differences noted between the groups at
baseline were by chance alone. Another strength of this study is that subjects were
screened for exposure to biofeedback. An assessment of HRV was made at
baseline prior to HRVB exposure. Changes in HRV between the assessments
were found to be causally related to HRVB training thus supporting the hypothesis
that improvement in HRV can improve pain severity, pain interference, the need
for non-steroidal anti-inflammatory drug use, as well as reaction time, and
depression.
A limitation of this study is that it only included US military veterans ages
18+ and therefore may not be generalizable to all populations. Information bias
could have resulted if participants had difficulty either recalling past information or
were indecisive in how to respond to a question. Furthermore, information bias
may have resulted if a participant decided not to answer (refused) a question (i.e.
income) or may have been magnified if, despite the confidentiality imposed by the
study protocol, they felt that information provided in this study may negatively
impact their financial compensation from the VA. Efforts were made to ensure
completeness of all questionnaires at the time they were completed and then,
using a neutral demeanor, participants were asked if the blank answer they
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provided was what they meant to provide. Staff were trained on how to transcribe
and code variables for accuracy and they performed a 10% audit of data at various
times. Interviewer bias was minimized by ensuring participant information was
coded. Participants were blinded to which group they were randomly enrolled and
upon completion, and the control group was offered the opportunity to receive the
HRVB training. Another limitation of this study was that participants who
volunteered may have differed from those who did not volunteer to participate. A
large limitation of this study due to the length of time involved over four months,
was loss-to-follow-up. Attempts were made to encourage participants to continue
to remain enrolled and when a participant decided to voluntarily disenroll or to not
make any more appointments, research staff inquired as to the reasoning to help
in the final analysis. Over 500 veterans were screened prior to enrollment. Of
these, many were not eligible due to uncontrolled hypertension or due to either a
beta-blocker or calcium channel blocker medication. This precluded participation
among some patients, yet exclusion of these patients helped prevent introduction
of other biases. Those who were younger were more likely to be lost-to-follow-up
rather than those who were older. Otherwise, no differences were noted among
those who completed the study versus those who were lost-to-follow-up in the
demographics or comorbid diseases (Tables 4.14 and 4.15).
A limitation of the PASAT has been noted with regional rates of diction.
Those with language or speech difficulties may have been placed at a
disadvantage and geographical or cultural speech patterns also may have
influenced PASAT outcomes.219 For example, this study was performed in the
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southeastern United States where some people may naturally speak with a slower
cadence. This could be weighed against the fact that the study sample was
comprised of former members of the military that grew up and served across the
US and the globe. However, Tombaugh notes that obtaining low scores on the
PASAT does not confirm pathology of the neurological system. Differences were
not observed in PASAT outcome between groups. In the present study,
improvements were found in both the HRVB group and the control group in the
PCS, PASAT, HVLT, and the number of Lapses in the PVT. This may be due to a
learning effect or that these tests may not be the best tests for this veteran
population.
In conclusion, HRVB is a safe, easily implemented, non-pharmacological
technique that can be used virtually anywhere and can help in the self-regulation
of symptoms such as pain and depression. Through the use of HRVB, HRV
coherence improved, pain severity and pain interference decreased, a reduction
in NSAID use was observed, depression decreased, and reaction time improved
in the intervention group relative to the control group. Larger studies conducted at
multiple sites should be conducted to further determine the efficacy of HRVB
among those with pain related symptoms in both veterans and the general
population.
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Figure A.3 Participant Questionnaire
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Figure A.4: CONSORT Flow Diagram
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